Generex Biotechnology (GNBTQ) 10-Q 21 Dec 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Oct. 31, 2020	Dec. 21, 2020
Document And Entity Information
Entity Registrant Name	GENEREX BIOTECHNOLOGY CORP
Entity Central Index Key	0001059784
Current Fiscal Year End Date	--07-31
Entity Filer Category	Non-accelerated Filer
Entity's Reporting Status Current	Yes
Entity Incorporation, State or Country Code	DE
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	000-25169
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Oct. 31, 2020
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding		109,983,989

UNAUDITED CONDENSED INTERIM CON

UNAUDITED CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS - USD ($)	Oct. 31, 2020	Jul. 31, 2020
Current assets
Cash and cash equivalents	$ 833,566	$ 15,452
Accounts receivable, net	183,928	164,871
Inventory, net	718,624	742,256
Other current assets	306,845	332,268
Total Current Assets	2,042,963	1,254,847
Property and equipment	175,513	213,668
Goodwill	34,489,342	34,489,342
Intangible assets	9,134,184	9,365,526
Operating lease right-of-use assets - net	22,003	38,140
Other assets	21,421	21,421
TOTAL ASSETS	45,885,426	45,382,944
Current liabilities
Accounts payable and accrued expenses	33,464,414	23,907,718
Notes payable, current	9,958,563	10,666,703
Payable to foundation for services	1,315,817	1,315,817
Interest payable to foundation	4,149,900	3,911,141
Loans from related parties	29,700	29,700
Operating lease liabilities - current	22,049	38,253
Refundable advances	2,000,000	0
Deferred tax liability	1,502,122	1,502,122
Total Current Liabilities	52,442,565	41,371,454
Notes payable - noncurrent, net of debt discount	499,839	499,656
Derivative liability	16,492,507	1,316,757
Common stock payable	8,483,393	10,079,449
Total Liabilities	77,918,304	53,267,316
Redeemable non-controlling interest (Note 10)	4,073,898	4,073,898
Stockholders' equity (defiency) (Note 9)
Common stock, $0.001 par value; 750,000,000 authorized shares; 108,037,614 and 82,251,801 issued and outstanding as of October 31, 2020 and July 31, 2020, respectively	108,037	82,251
Additional paid-in capital	418,411,365	429,744,379
Accumulated deficit	(464,643,597)	(452,062,905)
Accumulated other comprehensive income	778,094	780,296
Non-controlling interest	9,239,325	9,497,709
Total stockholders' deficiency	(36,106,776)	(11,958,270)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	45,885,426	45,382,944
Series A Cumulative Redeemable Perpetual Preferred Stock,
Stockholders' equity (defiency) (Note 9)
Series A Cumulative Redeemable Perpetual Preferred Stock, $0.001 par value per share; 1,000,000 authorized and no shares issued and outstanding as of both October 31, 2020 and July 31, 2020, respectively	$ 0	$ 0

UNAUDITED CONDENSED INTERIM C_2

UNAUDITED CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Oct. 31, 2020	Jul. 31, 2020
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	108,037,614	82,251,801
Common stock, shares outstanding	108,037,614	82,251,801
Series A Cumulative Redeemable Perpetual Preferred Stock,
Cumulative Preferred Stock, par value	$ 0.001	$ 0.001
Cumulative Preferred Stock, shares authorized	1,000,000	1,000,000
Cumulative Preferred Stock, shares issued	0	0
Cumulative Preferred Stock, shares outstanding	0	0

UNAUDITED CONDENSED INTERIM C_3

UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Income Statement [Abstract]
Revenue	$ 88,435	$ 721,661
Cost of Goods Sold	23,333	133,618
Gross profit	65,102	588,043
Operating expenses
Research and development	1,170,008	338,734
Bad debt expense	0	10,981
General and administrative	13,008,172	4,787,039
Total operating expenses	14,178,080	5,316,754
Operating Loss	(14,113,078)	(4,548,711)
Other Income (Expense):
Interest expense	(1,019,080)	(2,516,113)
Interest income	0	452
Change in fair value of common stock payable	123,230	0
Change in fair value of derivative liability	4,019,852	(2,239,422)
Other income, net	0	(8,753)
Net loss	(10,989,076)	(9,312,547)
Net loss attributable to noncontrolling interests	(258,384)	(186,602)
Net loss available to common stockholders	$ (10,730,692)	$ (9,125,945)
Basic	$ (0.11)	$ (0.13)
Diluted	$ (0.11)	$ (0.13)
Basic	96,859,079	69,800,583
Diluted	96,859,079	69,800,583
Comprehensive loss
Net loss available to common stockholders	$ (10,730,692)	$ (9,125,945)
Change in foreign currency translation adjustments	(2,202)	(294)
Comprehensive loss available to common stockholders	$ (10,732,894)	$ (9,126,239)

UNAUDITED CONDENSED INTERIM C_4

UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Sub Total	Noncontrolling Interest	Total
Beginning balance, shares at Jul. 31, 2019		78,608,419
Beginning balance, value at Jul. 31, 2019		$ 78,608	$ 408,550,211	$ (418,727,875)	$ 797,216	$ (9,301,840)	$ 16,974,439	$ 7,672,599
Stock compensation expense, value			787,458			787,458		787,458
Issuance of common stock payable, shares		296,793
Issuance of common stock payable, value		$ 297	921,598			921,895		921,985
Conversion of debt to equity, shares		1,164,190
Conversion of debt to equity, value		$ 1,164	1,735,673			1,736,837		1,736,837
Issuance of common stock for acquisitions, shares		960,000
Issuance of common stock for acquisitions, value		$ 960	1,150,992			1,151,952		1,151,952
Reduction of derivative liabilities			1,911,487			1,911,487		1,911,487
Settlement of derivative liability from exercise of warrants
Cancellation of shares, shares		(20,375,900)
Cancellation of shares, value		$ (20,376)	20,376
Purchase of shares in subsidiary			1,987,390			1,987,390	(1,987,390)
Issuance of stock options
Currency translation adjustment					(294)	(294)		(294)
Net loss				(9,125,945)		(9,125,945)	(186,602)	(9,312,547)
Ending balance, shares at Oct. 31, 2019		60,653,502
Ending balance, vlaue at Oct. 31, 2019		$ 60,653	417,065,185	(427,853,820)	796,922	(9,931,060)	14,800,447	4,869,387
Beginning balance, shares at Jul. 31, 2020		82,251,801
Beginning balance, value at Jul. 31, 2020		$ 82,251	429,744,379	(452,062,905)	780,296	(21,455,979)	9,497,709	(11,958,270)
Stock compensation expense, shares		51,130
Stock compensation expense, value		$ 51	1,221,801			1,221,852		1,221,852
Issuance of common stock payable, shares		3,529,415
Issuance of common stock payable, value		$ 3,529	1,469,297			1,472,826		1,472,826
Conversion of debt to equity, shares		5,860,255
Conversion of debt to equity, value		$ 5,860	1,121,982			1,127,842		1,127,842
Reduction of derivative liabilities			538,084			538,084		538,084
Issuance of common stock and warrants with attributed derivative liability from PIPE offering, shares		5,102,040
Issuance of common stock and warrants with attributed derivative liability from PIPE offering, value		$ 5,102	(19,729,318)			(19,724,216)		(19,724,216)
Deemed dividend related to issuance of warrants containing derivative liabilities			1,850,000	(1,850,000)
Settlement of derivative liability from exercise of warrants			1,840,530			1,840,530		1,840,530
Sale of common stock, shares		2,100,000
Sale of common stock, value		$ 2,100	354,610			356,710		356,710
Exercise of Series D warrants, shares		9,142,973
Exercise of Series D warrants, value		$ 9,144				9,144		9,144
Currency translation adjustment					(2,202)	(2,202)		(2,202)
Net loss				(10,730,692)		(10,730,692)	(258,384)	(10,989,076)
Ending balance, shares at Oct. 31, 2020		108,037,614
Ending balance, vlaue at Oct. 31, 2020		$ 108,037	$ 418,411,365	$ (464,643,597)	$ 778,094	$ (45,346,101)	$ 9,239,325	$ (36,106,776)

UNAUDITED CONDENSED INTERIM C_5

UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net (Loss) Income	$ (10,989,076)	$ (9,312,547)
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization	262,173	203,273
Amortization of operating lease right-of-use assets	16,137	18,887
Stock compensation expense	1,221,852	787,458
Loss of disposal of fixed assets	7,324	0
Amortization of debt discount	174,049	2,065,835
Change in fair value of derivative liabilities - convertible notes	111,150	(727,942)
Change in fair value of derivative liabilities - convertible warrants	(4,131,002)	(66,456)
Change in fair value of derivative liabilities - downside protection	0	3,033,820
Bad debt expense	0	10,981
Increase in notes payable due to default	255,080	0
Change in fair value of common stock payable	(123,230)	0
Changes in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable	(19,057)	4,024
Inventory	23,632	(98,184)
Accounts payable and accrued expenses	9,607,304	2,366,230
Interest payable to foundation	238,759	0
Loans from related parties	0	52,912
Refundable advance	2,000,000	0
Other current assets	(16,204)	(163,596)
Other current liabilities	25,423	(18,500)
Net cash used in operating activities	(1,335,538)	(1,843,805)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	0	(4,451)
Cash received in acquisition of a business, net of cash paid	0	49,305
Net cash provided by investing activities	0	44,854
CASH FLOWS FROM FINANCING ACTIVITIES
Payment of notes payable	(60,000)	(935,731)
Proceeds from note payable	0	2,976,745
Proceeds from issuance of common stock	356,710	0
Proceeds from issuance of common stock and warrants in PIPE offering, net of fees of $150,000	1,850,000	0
Proceeds from exercise of warrants	9,144	0
Net cash provided by financing activities	2,155,854	2,041,014
Effects of currency translation on cash and cash equivalents	(2,202)	(294)
Net increase in cash and cash equivalents	818,114	241,769
Cash and cash equivalents, beginning of period	15,452	298,485
Cash and cash equivalents, end of period	833,566	540,254
Supplemental Disclosure of Cash Flow Information
Cash paid for interest	50,000	25,000
Cash paid for taxes	0	0
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Reduction of derivative liabilities	538,084	1,911,487
Discount on derivative liability upon issuance of debt	1,472,826	1,052,349
Issuance of common stock for conversion of debt	1,127,840	1,694,851
Recording of right of use asset and liability	0	116,440
Increase common stock payable	0	14,500
Issuance of shares--common stock payable	0	921,895
Derivative liability in connection with issuance of warrants from PIPE offering	21,574,216	0
Settlement of derivative liability from exercise of warrants	$ 1,840,530

UNAUDITED CONDENSED INTERIM C_6

UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)	3 Months Ended
	Oct. 31, 2020USD ($)
Statement of Cash Flows [Abstract]
Fees	$ 150,000

Organization of Business and Go

Organization of Business and Going Concern	3 Months Ended
	Oct. 31, 2020
Accounting Policies [Abstract]
Organization of Business and Going Concern	Note 1 – Organization of Business and Going Concern: Generex Biotechnology Corporation (“Generex”, “Company”, “GNBT”, "we", "us" or "our"), was formed in the State of Delaware on September 4, 1997 and its year-end is July 31. As of October 31, 2020, the active subsidiaries of the Company are Generex Pharmaceuticals, Inc.; 1097346 Ontario, Inc.; NuGenerex Immuno-Oncology, Inc.; Nugenerex Diagnostics, Inc.; Rapid Medical Diagnostics Corporation; GNBTELC, LLC; Olaregen Therapeutix, Inc.; Regentys Corporation; Nugenerex Management Services, Inc.; Nugenerex Distribution Solutions 2, LLC; DMEiq, LLC (d/b/a DME-IQ); Rapport Services, LLC; NMSIELC, LLC; High Desert Diagnostic Laboratory, Inc.; NuGenerex Distribution Solutions, LLC; Pantheon F & A, LLC; Nugenerex Surgical Holdings, LLC; NuGenerex Health, LLC; NuGenerex HMO, LLC; NuGenHealth, LLC; and NuGenerex MSO, LLC. Generex is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. On October 3, 2018, the Company entered into an Asset Purchase Agreement with Veneto Holdings, L.L.C. (“Veneto”) to purchase certain assets of Veneto and its subsidiaries to formulate Nugenerex Distribution Solutions 2, LLC (“NDS 2”). The Agreement bifurcated the closing. On October 3, 2018 (the “First Closing”), the Company purchased substantially all the operating assets of Veneto including (a) system of dispensing pharmacies, (b) one central adjudicating pharmacy, (c) a wholesale pharmaceutical purchasing company, and (d) an in-network laboratory. On November 1, 2018, the Company consummated the acquisition of the Second Closing Assets, consisting primarily of Veneto’s management services organization business and two additional ancillary services. In March 2019, the Company changed its business model to no longer utilize the existing pharmacies. Going forward Veneto will conduct business exclusively through its management services organization (“MSO”) and by entering into more ancillary provider service agreements with third party pharmacies as an effort to reduce fixed costs and salaries. This was made practicable due to the decrease in overall script volume coupled with delays in the Company being able to receive operating licenses from various government agencies. On January 7, 2019, the Company closed two separate Acquisition Agreements pursuant to which the Company acquired a 51% interest in both Regentys Corporation (“Regentys”) and Olaregen Therapeutix Inc. (“Olaregen”). Regentys is a regenerative medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders. Olaregen is a New York based regenerative medicine company that is preparing to launch its proprietary, patented, wound conforming gel matrix, Excellagen, an FDA 510K cleared wound healing product. In the first quarter of 2020 the Company acquired increased its ownership of Olaregen to 77%. In the third quarter of 2020 the Company acquired the remaining interest in Olaregen in exchange for its shares of common stock and became a wholly owned subsidiary of the Company. On August 1, 2019, the Company, through its wholly owned subsidiary NDS, closed on Asset Purchase Agreements (the “APAs”) for the purchase of substantially all the operating assets of MediSource Partners, LLC (“MediSource”) and Pantheon Medical - Foot & Ankle, LLC (“Pantheon”). MediSource contracts with vendors (including Pantheon) for nationwide distribution of implants and devices for spine, hips, knees, foot, ankle, hand, and wrist surgeries. Additional product lines include biologics (blood, bone, tissue, and stem cells), durable medical equipment, and soft goods. MediSource also supplies kits to process bone marrow aspirates and platelet rich plasma biologics at the time of surgery. Pantheon sells a physician friendly, “all-in-one,” integrated kit that includes plates, screws, and tools required for orthopedic surgeons and podiatrists conducting foot and ankle surgeries. Over the next three years, Pantheon expects to develop and submit several new product lines to the FDA, which will include cannulated surgical screws and surgical staples, as well as a proprietary Hammertoe System. Since July 20, 2020, the termination of the Travis Brid consulting agreement and the COVID-19 pandemic have curtailed the operations of MediSource and Pantheon and as result, the goodwill and intangibles were fully impaired. On August 25, 2020, Generex Biotechnology Corporation’s wholly owned subsidiary NuGenerex Health LLC, (“NuGenerex Health”), entered into a strategic joint venture with Worldwide Digitech, LLC (“WWDT”) by signing an Operating Agreement to form NuGenHealth LLC (“NuGenHealth”). Under the agreement profits shall be distributed equally; 50% to NuGenerex Health LLC and 50% to WWDT. WWDT will provide the software powered by the HealthKOS framework and back-end support for the NuGenHealth SaaS system, while NuGenerex Health LLC shall be responsible for the day-to-day management and oversight of business operations along with operating capital totaling approximately $1,500,000. On September 24, 2020, NuGenHealth, LLC, a subsidiary of Generex Biotechnology Corporation, signed a services agreement with Paradise Valley Family Medicine, P.C. an Arizona professional corporation (“PVFM”) to provide a software and services solution for patient engagement, Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) services that are recommended and reimbursed by the Centers of Medicare and Medicaid Services (CMS). Going Concern The accompanying unaudited condensed interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate continuation of the Company as a going concern. The Company has experienced recurring net losses and negative cash flows from operations since inception and has an accumulated deficit of $464,643,597 and a working capital deficiency of $50,399,602 on October 31, 2020. The Company has funded its activities to date almost exclusively from debt and equity financings. The Company will continue to require substantial funds to implement its new investment acquisition plans. Management’s plans in order to meet its operating cash flow requirements include financing activities such as private placements of its common stock, preferred stock offerings, and issuances of debt and convertible debt instruments. Management is also actively pursuing financial and strategic alternatives, including strategic investments and divestitures, industry collaboration activities and strategic partners. The recent, widespread outbreak of a novel infectious disease called Coronavirus Disease 2019, or COVID-19, has created a dynamic and uncertain situation in the national economy. Regarding the Company, sales of Olaregen's Excellagen have been significantly impacted by the COVID-19 pandemic. Surgeries and outpatient procedures were delayed and rescheduled, severely limiting sales of wound care and surgical products. Going forward, as the VA and other hospital systems re-open, the re-scheduled surgeries and procedures are expected to start up and create a backlog of cases, which should accelerate product sales to pre-COVID levels in due course. As a result of the termination of the Travis Bird Consulting Agreement and the ongoing COVID-19 pandemic, the operations of Medisource and Pantheon have been significantly curtailed resulting in no sales for during the current quarter ending October 31, 2020 compared to $449,196 for the same period in the prior year with no expectation that such sales will resume in the near future. Because of the COVID-19 pandemic Generex and its subsidiaries are currently pursuing the development of a SARS-CoV-2 vaccine using the company's patented Ii-Key peptide vaccine technology. To this end, the Company applied for funding to BARDA in the U.S., Health Canada, and the Malaysian Ministry of Health as well as with CEPI, the international public/private consortium focused on the development of vaccines for the global market. To date, Generex has identified viral epitopes through computer vaccinology algorithms, and manufactured those peptide sequences with the Ii-Key moiety for testing in immunological screening program using convalescent blood samples from patients who have recovered from COVID-19. The immunological blood screening program is in progress. Manufacturing partners have been identified and contracted for clinical and commercial supply. Completion of the Ii-Key-SARS-CoV-2 peptide vaccine program is being funded through a partnership with international partners, including Bintai Kinden. The Company continues to closely monitor the latest information to make timely, informed business decisions and public disclosures regarding the potential impact of pandemic on its operations and financial condition. The scope of pandemic is unprecedented and its long-term impact on the Company’s operations and financial condition cannot be reasonably estimated at this time. There is always uncertainty and risk associated with the development of any vaccine, medical treatment or therapy, but the continued development depends upon the completing the trials under various collaboration agreements and associated potential commercialization of the product, FDA approval and/or licensing agreements. Any collaborator with whom we may enter into such collaboration agreements may not support fully our research and commercial interests since our program may compete for time, attention and resources with such collaborator's internal programs. Therefore, these collaborators may not commit sufficient resources to our program to move it forward effectively, or that the program will advance as rapidly as it might if we had retained complete control of all research, development, regulatory and commercialization decisions. During the pandemic COVID-19, it is anticipated that delays will occur, but the full impact of any slow down due to COVID-19 has not been determined. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the filing of this document. There are no assurances that such additional funding will be achieved and that the Company will succeed in its future operations. The unaudited condensed interim consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s inability to obtain required funding in the near future or its inability to obtain funding on favorable terms will have a material adverse effect on its operations and strategic development plan for future growth. If the Company cannot successfully raise additional capital and implement its strategic development plan, its liquidity, financial condition, and business prospects will be materially and adversely affected, and the Company may have to cease operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Oct. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies: Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments, considered necessary for a fair presentation have been included. The Company’s fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated. Operating results for the three months ended October 31, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2021. The balance sheet on October 31, 2020 does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Therefore, these condensed financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended July 31, 2020 as filed with the U.S. Securities and Exchange Commission (“SEC”). Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from those estimates. Business Combinations Business combinations are accounted for using the acquisition method of accounting. Acquisition cost is measured as the aggregate of the fair value at the date of acquisition of the assets given, equity instruments issued, or liabilities incurred or assumed. Acquisition related costs are expensed as incurred (except for those costs arising on the issue of equity instruments which are recognized directly in equity). Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured at fair value on the acquisition date. Goodwill is measured as the excess of the acquisition cost and the amount of any non-controlling interest, over the fair value of the identifiable net assets acquired. Revenue Recognition It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 “Revenue Recognition.” Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Revenue from NGDx is recognized upon payment at the time the product(s) is released (shipment delivered using a common carrier), and the control is transferred which is simultaneous to when payment received and accepted. Revenue from product sales of Olaregen’s Excellagen® is recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government rebates. Revenue from product sales of Pantheon medical surgical kits used in surgical procedures is recorded all revenue is recognized at a point in time, generally when title of the product and control is transferred to the client which occurs upon the completion of surgical procedure when the product utilized and the medical facility provides a final list of products consumed. The Company constrains revenue by considering factors that could otherwise lead to a probable reversal of revenue. Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as the Company’s historical experience, contractual arrangement and specific known market events and trends. Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers. Revenue from the provision of management services is recognized in accordance with the contractual terms of the relationship (item i); however, the current agreements in place typically specify that a percentage of the gross margin associated with the third-parties’ sales that the Company facilitates is to be remitted (iii), and as such, the revenue is considered earned upon completion of the third parties’ sales of such products (iv). Three months ended October 31, Revenue Source 2020 2019 Product sales $ 88,435 $ 713,405 Management services — 8,256 Total Revenue $ 88,435 $ 721,661 Provisions for estimated sales returns and uncollectible accounts are recorded in the period in which the related sales are recognized based on historical and anticipated rates. Adoption of New Accounting Standards In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment Recently Issued Accounting Standards In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, and ASU 2019-05 (collectively, “Topic 326”). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. The Company will be required to adopt this ASU for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The adoption of Topic 326 is not expected to have a material on the Company’s consolidated financial statements and financial statement disclosures. In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Company. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Oct. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 3 - Commitments and Contingencies: Pending Litigation The Company is a defendant in one legal proceeding relating to alleged breach of contract and claims against certain of the Company’s original buccal delivery patents. The Company is also a defendant in two legal proceedings brought by a former executive officer and her affiliate. These legal proceedings have been reported in the Company’s prior periodic reports. No activity has occurred in these cases in several years, and the Company now considers them dormant. In December 2011, a vendor of the Company commenced an action against the Company and its subsidiary, Generex Pharmaceuticals, Inc., in the Ontario Superior Court of Justice claiming damages for unpaid invoices including interest in the amount of $429,000, in addition to costs and further interest. The Company responded to this statement of claim and also asserted a counterclaim in the proceeding for $200,000 arising from the vendor’s breach of contract and detinue, together with interest and costs. On November 16, 2012, the parties agreed to settle this action and the Company has agreed to pay the plaintiff $125,000, following the spinout of its subsidiary NGIO, from the proceeds of any public or private financing related to NGIO subsequent to such spinout. Each party agreed to execute mutual releases to the claim and counterclaim to be held in trust by each party’s counsel until payment of the settlement amount. Following payment to the plaintiff, the parties agree that a Consent Dismissal Order without costs will be filed with the court. If the Company fails to make the payment following completion of any post-spinout financing related to NGIO or any other subsidiaries, the Plaintiffs may take out a judgment in the amount of the claim plus interest of 3% per annum and costs fixed at $25,000 which has been accrued as of October 31, 2020. On August 22, 2017, Generex received a letter from counsel for Three Brothers Trading LLC, d/b/a Alternative Execution Group (“AEXG”), claiming breach of a Memorandum of Understanding (“MOU”) between Generex and AEXG. The MOU related to AEXG referring potential financing candidate to Generex. The letter from AEXG counsel claimed that Generex’s acceptance of $3,000,000 in financing from Pharma Trials, LLC, in March 2017, violated the provisions of the MOU prohibiting Generex from seeking other financing, with certain exceptions, for a period of 60 days after execution of the MOU. AEXG has demanded at least $210,000 in cash and 84,000 warrants for Generex stock convertible at $2.50 per share, for attorney’s fees and costs. AEXG filed a demand for arbitration and on September 25, 2018 an arbitration hearing was held with an arbitrator from the American Arbitration Association’s International Centre for Dispute Resolution. On December 3, 2018, an arbitrator awarded AEXG an aggregate of $315,695 in damages, costs and fees as well as warrants exercisable for 84,000 shares of Generex Common Stock at an exercise price of $2.50 per share. AEXG filed a petition to confirm the arbitrator’s award in the United States District Court for the Southern District of New York. The petition includes a demand of $3,300,360 as the value of the warrants. The arbitrator did not award the specific amount of $3.5 million, but only liquidated damages in the amount of $210,000 and the value of 84,000 warrants “as of today” (the date of the award) plus attorney’s fees, certain costs, prejudgment and post-judgment interest (which continues to run on a daily basis) and arbitration fees. Generex has responded that the value of the warrants on the date of the award is $0 or some figure far less than the value calculated by AEXG. The petition to confirm the arbitrator’s award and Generex’s opposition were remanded by the Court to the arbitrator and returned for clarification. The arbitrator stated that he was unable to add any clarification, as he did not take evidence on the issue of warrant valuation. AEXG filed a petition and on April 24, 2020, the Court issued an Opinion and Order in the Litigation confirming the portions of the Arbitration Award regarding liquidated damages, pre-judgment interest, legal fees, and costs, but remanding to the Arbitrator for further proceedings the portion of the Arbitration Award relating to “the economic value today of 84,000 warrants convertible to Generex’s stock exercisable at $2.50 per share as of September 24, 2018” (the “Remanded Arbitration”). On September 18, 2020, the Court issued that AEXG recover from Generex the total sum of $384,771, which sum consists of $210,000 in liquidated damages, $93,304 in legal fees, $12,393 in arbitration fees, $3,313 in arbitration expenses, $65,762 in pre-judgment interest, and post-judgment interest at a rate established by 28 U.S.C § 1961 from September 18, 2020, until the judgment is satisfied (the “Partial Final Judgment”). The parties settled and agreed to the terms of the Partial Final Judgment that included a payment schedule to which Generex has paid $200,000 in cash to date with the remaining balance being paid and retired in 30 days. The settlement terms do not apply, settle, or resolve in any manner the Remanded Arbitration or the issues pending therein, including, but not limited to, the economic value of the 84,000 warrants, Generex’s right to contest AEXG’s attorneys’ fees, or Generex’s right to contest the issue of who is the prevailing party for fees other than those fees awarded in the Arbitration Award. Generex continues to vigorously defend the open matters. As of October 31, 2020, the Company has accrued approximately $450,000 related to this matter. On June 28, 2018, the Company was named in respect of a claim by Burrard Pharmaceutical Enterprises Ltd. and Moa’yeri Kayhan for unspecified damages and other remedies issued by the Supreme Court of British Columbia. The claim is made in connection with one advanced against Burrard and Kayhan by Middle East Pharmaceutical Factory L.L.C., a foreign corporation, for fraudulent or negligent misrepresentation. Middle East alleges that it was misled by Burrard and Kayhan into believing that Burrard had rights to distribute Generex product in the Middle East. Burrard and Kayhan allege that they did have rights in that regard, which the Company denies. The matter remains at the pleadings stage and the Company is investigating the facts. On October 26, 2018, Generex entered into a securities purchase agreement with Alpha Capital Anstalt (“Alpha”) pursuant to which a note due on October 26, 2019 was called for repayment in the principal amount of $682,000. On March 21, 2019 Compass Bank filed suit against NuGenerex Distributions Solutions 2, L.L.C. (“NDS”) in the District Court of Dallas County, Texas requesting damages of $3,413,000. This lawsuit is directly connected to assets that were supposed to be transferred to NDS from a third party, but never were transferred. Compass Bank had a lien on those certain assets that were supposed to be transferred into the ownership of NDS, a subsidiary of Generex. NDS and Generex shall continue to defend this legal matter. As of October 31, 2020, the Company has accrued $3,416,695 related to this matter. In May 2019 Brooks Houghton threatened litigation by way of a FINRA Dispute Resolution. Brooks Houghton, who the managing representative is Mr. Centonfanti a prior board member, was under contract to perform due diligence on the Veneto transaction, as well as other unrelated items. The Veneto transaction closed three times, each time with a reduction in price due to material negative circumstances. Brook Houghton, who was under contract to perform due diligence, claims their fee should be paid on the initial closing price not the ultimate resolution of the matter. The company offered to compensate Brooks Houghton pursuant to agreement, 3% on the most recent closing price for Veneto for which Brooks Houghton may have performed some level of work on, payable in kind, and Brooks Houghton declined the offer. Brooks Houghton is claiming $450,000 for the first closing of Veneto, $714,000 for the second closing of Veneto, $882,353 for the Regentys acquisition, and $705,882 for Olaregen. The Company shall continue to defend this legal matter. As of October 31, 2020, the Company has accrued for the full $2,752,235 balance. On September 9, 2019 Generex and its subsidiary NuGenerex Distribution Solutions, LLC, and NuGenerex Distributions Solutions 2, LLC (jointly “NDS”) filed a litigation against Veneto, and the constituent entities, for fraud, breach of contract, and a motion for a temporary restraining order restraining the shares contemplated in the Asset Purchase Agreement (“APA”) (supra) for hiding their involvement in a massive healthcare fraud scheme, which is currently being prosecuted civilly by the federal government and filing to transfer assets specified in the APA. . Our motion for a temporary restraining order on transfer of shares we issued in connection with the acquisition of Veneto assets was denied by the Court of Chancery. Generex has continued to pursue claims against Veneto and its principals in a separate arbitration. In a related action, our transfer agent for our common stock was sued for failure to process a transfer of the shares issued pursuant to the APA. This suit was brought in the United States District Court for the Eastern District of New York. Generex was not named in the suit, but our transfer agent notified us of our obligation to indemnify them pursuant to our agreement with the transfer agent. The action against the transfer agent was dismissed with prejudice and on consent on November 25, 2019. On December 2, 2019 the Company was named as a respondent in an arbitration brought by KSKZ Management, LLC before the American Arbitration Association in Texas. The Claimant alleges that the Company breached a consulting agreement that purportedly obligated the Company to pay claimant a monthly consulting fee for three years. Kevin Kuykendall is the manager and a member of Claimant. Claimant is seeking approximately $3,450,000 in unpaid consulting fees allegedly due. The Company is vigorously defending itself and has filed counterclaims against Claimant. The Company believes that the likelihood of an unfavorable outcome is remote and as result has not accrued anything for this claim. On February 18, 2020 the Company was named as a defendant in an action brought by Discover Growth Fund, LLC in the United States District Court for the District of Delaware. The plaintiff alleges that the Company breached a Purchase Agreement and Promissory Note and seeks $2,475,000 in damages. The plaintiff also filed a confession of judgment in support of its claim. On May 4, 2020 the District Court entered judgment against the Company in the amount of $2,200,000. Counsel for Generex and Discover have engaged in settlement discussions. In addition, on August 20, 2020 the Company was named as a defendant in an action brought by Discover Growth Fund, LLC in the Court of Chancery of the State of Delaware. The complaint alleges that the Company breached a Purchase Agreement, Promissory Note and Transfer Agent Instructions and seeks to compel the Company to honor notices of conversion from Discover Growth Fund, LLC and issue it shares pursuant to the Purchase Agreement and Promissory Note. Discover has since dropped the Delaware case without prejudice. The Company has accrued approximately $2,500,000 as of October 31, 2020. On May 6, 2020, the Company was named as a defendant in an action brought by Iliad Research and Trading LP in Salt Lake City, Utah. The plaintiff alleged that the Company breached a Securities Purchase Agreement and Convertible Promissory Note. Arbitration commenced on this matter on or about July 1, 2020 and was settled on July 31, 2020. In settlement of the matter (including any amounts outstanding under the Convertible Promissory Note), the Company has issued Iliad 3,499,415 shares of the Company’s common stock. The arbitration was dismissed on August 14, 2020. On October 2, 2020, the Company and its subsidiary, NuGenerex Distribution Solutions, LLC, was named as a defendant in an action brought by AVEM Medical, LLC, formerly known as Medisource Partners, LLC and Pantheon Medical – Foot & Ankle, LLC in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida, Civil Division. The complaint alleges that the Company breached an Asset Purchase Agreement by issuing fewer shares to the seller than what the agreements contemplated. AVEM claims entitlement to an additional $312,000 in Company stock, and Pantheon claims entitlement to an additional $576,800 in Company stock. The Company has filed a motion to dismiss the case for lack of subject matter jurisdiction, and it intends to vigorously defend the case wherever it is ultimately litigated. The Company intends to vigorously defend the case, and nothing is accrued at this time. With respect to all litigation, as additional information concerning the estimates used by the Company becomes known, the Company reassesses its position both with respect to accrued liabilities and other potential exposures. Commitments Intellectual Property In connection with the Company’s acquisition of Olaregen, intellectual property was acquired that had a valuation of $650,000 prior to being acquired and revalued. This initial $650,000 valuation represented the initial payment remitted by Olaregen in accordance with the $4 million signed commitment agreement entered into with Activation Therapeutics, Inc. The remaining $3.35 million balance is to be paid in quarterly installments equal to 10% of quarterly net sales generated by Activation Therapeutics assuming the Exellagen average selling price per unit exceeds $800. In the event that the average selling price per unit is less than $800 per unit, cost of goods sold shall be excluded from the computation of net sales. Acquisitions ALTuCELL On November 22, 2019, the Company entered into a Stock Purchase Agreement (“SPA”) for the purchase of 51% of the outstanding capital stock of GH Care, Inc. DBA ALTuCELL, Inc.(“ALTuCELL” ) Under the SPA, in exchange for the ALTuCELL Stock, Generex will issue to ALTuCELL 2,240,000 shares of Generex common stock with an attributed value of $4 million to be issued at the market price of the day at closing, but no less than $0.89 per share. The Company will also pay $2.5 million in cash of which $212,000 has already been paid. In addition to stock and cash at closing, Generex has agreed to pay up to an aggregate of $3,500,000 to ALTuCELL upon ALTuCELL’s attainment of certain milestones. On January 27, 2020, Generex and ALTuCELL executed an Amendment Agreement to the SPA (the “Amendment”). Under the Amendment, closing will occur within 30 days of the full execution of the Amendment, subject to the conditions to closing under the SPA. The parties agreed that Generex will pay the $2.5 million closing payment from certain specifically identified sources. If ALTuCELL chooses to cancel the transaction as a result of delays due to forces beyond the control of Generex, including government regulatory delays or extended reviews by regulators that delay approvals of corporate actions, or by natural disasters or other unforeseen events beyond the control of Generex, ALTuCELL, agrees to return all payments made by Generex. As of October 31, 2020, Generex has advanced $212,000 to ALTuCELL. As of the date of this filing, the acquisition did not close, however, both companies are negotiating the terms of the extension. Olaregen On November 24, 2019, the Company amended the Stock Purchase Agreement with Olaregen. The Company was obligated to pay in full $11,600,000 to Olaregen by November 30, 2019, in connection with the purchase of Olaregen capital stock (the “Olaregen Note”). Effective November 24, 2019, the deadline was extended to January 31, 2020. On February 14, 2020, the Company agreed to exchange 4,250,000 shares of Generex Common Stock and 1,065,000 shares of NGIO for the remaining outstanding shares of Olaregen with a waiver of any penalties and accrued interest on the outstanding Olaregen Note. As a result, Olaregen become wholly owned by the Company. Regentys On November 25, 2019, the Company amended the Stock Purchase Agreement with Regentys originally on January 7, 2019. Effective November 25, 2019, the remaining three payments of $2,039,001, $2,000,000, and $3,000,000 were all payable on or before December 30, 2019. The Company is negotiating the terms of a new extension and there has been no demand for payment at this time. MediSource – Pantheon On August 1, 2019, the Company, through its wholly owned subsidiary NDS, closed on Asset Purchase Agreements (the “APAs”) for the purchase of substantially all the operating assets of MediSource and Pantheon which provided the Pantheon Earn-out and MediSource Earn-out based about the EDITDA achieved by Patheon and MediSource. Neither earn-out was achieved nor anticipated for the remainder of the earn-out period and therefore the liability for contingent consideration was relieved. On July 20, 2020, Travis Bird terminated his consulting agreement with the Company and Travis Bird caused the operations of MediSource and Pantheon to curtail. As of this filing, no resolution and/or settlement has been reached and there is no guarantee that these operations will resume. This event has led to the full impairment of goodwill and intangibles of MediSource and Pantheon for the fiscal year ended July 31, 2020. Agreements Research and Development Agreements On November 20, 2018, the Company entered into a clinical trial agreement with NSABP Foundation, Inc. (“NSABP”) under which NSABP will conduct clinical research using the Company’s AE37 peptide immunotherapeutic vaccine in combination with pembrolizumab (Ketruda®) for the treatment of metastatic triple negative breast cancer. The Company has agreed to pay NSABP an amount not to exceed $2,118,461 based on NSABP achieving various milestones. The Company recognized $0 and $251,765 as research and development related to the clinical trial agreement with NSABP for the three-month periods ended October 31, 2020 and 2019, respectively. On June 2 Laboratory calls for Pursuant to this agreement, Generex will pay to CTL a fee for work plan completion an amount not to exceed $939,478. As of October 31, 2020, $562,063 is accrued under this agreement. COVID-19 Collaboration Agreement On October 5, 2020, the Company entered into a Distribution and Licensing Agreement (the “Agreement”) with Bintai Healthcare SDN BHD, a subsidiary of Bintai Kinden Corporation Berhad of Malaysia (“Bintai”) for the exclusive rights to distribute, sell, develop and commercialize the Generex Ii-Key-SARS-CoV-2 coronavirus vaccine (the “Vaccine”) in Malaysia and South East Asia countries, with right of first refusal to commercialize the Vaccine within New Zealand, Australia and the Global Halal markets (the “Territory”). The Agreement, among other things, consists of Bintai providing 100% funding for U.S. clinical development, manufacturing and commercial registration of the Vaccine for the Territory and paying Generex the following fees: a. $2,625,000 – Pre-Commercialization Stage Fees (inclusive for intellectual property rights, regulatory fees, and legal fees) b. $10,000,000 – Commercialization Stage Fees The Company has received $2,000,000 as refundable advance related to this distribution and licensing agreement for the three-month ended October 31, 2020. If the Company fails to secure FDA approvals within 6 months of execution of the agreement, or a reasonable time thereafter, the advance must be returned to Bintai. On October 30, 2020, Generex Biotechnology Corporation and its majority owned subsidiary NuGenerex Immuno-Oncology, Inc., (collectively “Generex”) signed a Framework Agreement on Cooperative Development of Coronavirus Peptide Vaccine with Beijing Youfeng International Consulting Co., Ltd, Chinese Centre for Disease Control and Prevention National Institute for Viral Disease Control and Prevention (NIVDC) and Beijing Guoxin Haixiang Equity Investment Partnership (Limited Partnership) (collectively referred to as “China Partners”) to jointly develop and industrialize the Generex Ii-Key-SARS-CoV-2 coronavirus peptide vaccine (the “Vaccine”) in the People’s Republic of China (“China”). The agreement, among other things, consists of the China Partners providing 100% funding for the clinical development, manufacturing and commercial registration of the Vaccine for China and paying Generex fees that shall be negotiated and agreed upon in subsequent agreements. Employee Compensation and Settlement Agreements During the three months ended October 31, 2020, the Company awarded executives and employees bonus compensation of $7,005,416 to be paid in approximately $1 million in cash and $6 million in stock. The cash portion is to be paid out before December 31, 2020 and the stock portion is expected to be issued by January 31, 2021. Payable to Foundation On February 1, 2007, the Company entered into a clinical study agreement with the Henry M. Jackson Foundation (the “Foundation” for the clinical research and development of AE37 for the treatment of breast cancer). The Company agreed to pay the foundation total compensation of $2,700,000 payable at various intervals over the term of the agreement. On September 9, 2013, the Company entered into a forbearance agreement (the “Forbearance Agreement”) with the Foundation, under which the Company n acknowledged that they were in arrears on its payment and interest obligations to the Foundation in the amount of $1,315,817. Pursuant to the Forbearance Agreement, the Company and the Foundation agreed that in exchange for deferring the overdue payments the Company would among other matters, pay the foundation (i) the final $200,000 upon completion of the study and acceptance of all study documents, (ii) a royalty of 5% of net third party sales and (iii) the original forbearance amount will continue to bear interest at 1.5% per month, compounded. The Foundation may terminate the Forbearance Agreement by providing the Company written notice should the Company, among other matters, fail to make payments due under the Forbearance Agreement. The foundation has not provided the study documents to the Company. The Foundation has not notified the Company that it is in default of any of its obligations under the Forbearance agreement. Effective August 1, 2015, the Company capitalized all outstanding unpaid interest on the outstanding balance. For the period ended October 31, 2020 and 2019, the Company recorded interest expense in the amount of $238,759 and $199,685, respectively, in the statements of operations. As of October 31, 2020 and July 31, 2020, the Company has recorded accrued interest of $4,149,900 and $3,911,141, respectively.

Inventory

Inventory	3 Months Ended
	Oct. 31, 2020
Inventory Disclosure [Abstract]
Inventory	Note 4 – Inventory Inventory consists of the following components: October 31, July 31, 2020 2020 Raw materials $ 182,722 $ 182,722 Finished goods 535,902 559,534 Total Inventory $ 718,624 $ 742,256

Property and Equipment

Property and Equipment	3 Months Ended
	Oct. 31, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 5 – Property and Equipment Property and equipment, net consisted of the following: October 31, July 31, 2020 2020 Computers and technological assets $ 50,205 $ 53,314 Machinery and equipment 317,751 329,977 Furniture and fixtures 18,725 18,725 Leasehold Improvements — 16,596 386,681 418,612 Less accumulated depreciation (211,168 ) (204,944 ) $ 175,513 $ 213,668 Depreciation expense related to property and equipment for the three months ended October 31, 2020 and 2019 was $30,831 and $48,847, respectively. Additionally, the Company disposed of $7,324 worth of fixed assets during the three months ended October 31, 2020.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Oct. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Note 6 – Goodwill and Intangible Assets The goodwill was recognized as a result of the acquisitions of Veneto, Regentys and Olaregen in fiscal year 2019. Goodwill was $ 34,489,342 Intangible assets consist of the following at: Estimated October 31, July 31, Useful Lives 2020 2020 In-Process Research & Development $ 6,302,427 $ 6,302,427 Non-compete agreements 3 years 1,210,000 1,210,000 Developed software/technology 5 years 131,000 131,000 Intellectual Property 5 years 2,459,000 2,459,000 Patents 20 years 51,274 51,274 10,153,701 10,153,701 Less accumulated amortization (1,019,517 ) (788,175 ) $ 9,134,184 $ 9,365,526 Intangible assets are amortized on a straight-line basis over the useful lives of the assets. The Company is currently not amortizing the in-process research and development until it becomes commercially viable and placed in service. At the time when the intangible assets are placed in service the Company will determine a useful life. As of October 31, 2020, the in-process research and development (“IPR&D”) of $6,302,427 in the aggregate was a combination of $2,911,377 obtained through the acquisition of HDS and $3,391,050 obtained through the acquisition of Regentys. None of the research and development of the underlying IPR&D have been abandoned, nor was it determined to be impaired by management as a result of COVID-19. On March 20, 2020, the Company was recently awarded a Blanket Purchase Agreement (BPA) contract from the National Strategic Acquisition Center (SAC). The VA’s National Contract and National BPA programs are used by VA medical centers, related facilities, specific State Veterans Homes, and other Federal facilities to procure select products based on clinical evidence, patient outcomes, and economic cost to the VA hospitals. The SAC awarded Olaregen’s Excellagen will expedite the purchasing of Excellagen at over 165 VA medical centers across the U.S. and Puerto Rico. This approval process was critical to the Company’s ability to determine that IPR&D associated with Olaregen, valued at $2,459,000, no longer has an indefinite life subject to amortization. The Company determined Olaregen’s IPR&D useful life to be 5 years. Amortization expense amounted to $231,342 and $154,426 for the three months ended October 31, 2020 and 2019, respectively. The estimated amortization expense remainder of the current fiscal year and for the next five years and thereafter is as follows: Year Ending July 31, Amount For the nine months ended July 31, 2021 $ 692,555 2022 654,190 2023 520,564 2024 500,914 2025 458,202 Thereafter 5,332 Total $ 2,831,757

Notes Payable

Notes Payable	3 Months Ended
	Oct. 31, 2020
Debt Disclosure [Abstract]
Notes Payable	Note 7 – Notes Payable On October 26, 2018, Generex entered into a Securities Purchase Agreement with an investor pursuant to which the Company sold its Note Due October 26, 2019 (“Note”) in the principal amount of $682,000 . In May 2019, the Company consummated a Stock Purchase Agreement entered into January 14, 2019 to which the Company sold a $2,000,000 promissory note bearing interest at 7% per annum originally due and payable on August 1, 2019. The notes remain active and interest has continued to accrue while new terms of the note are in process of being negotiated. In August 2019, the Company borrowed $1,000,000 from an investor, bearing 10% interest per annum, with an original issue discount of $150,000. This note is due in one year from the date of issuance. In August 2019, the Company entered into Securities Purchase Agreements to which the Company sold convertible note, bearing 10% interest per annum, in the principal amount of $1,100,000. The purchase price was $1,000,000 and the remaining 100,000 of principal amount represents original issue discount. Subject to certain ownership limitations, the Notes will be convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price determined as follows: 80% of the lowest trading price of the common stock on the ten days prior to conversion. The embedded beneficial conversion feature in these Notes meets the definition of a derivative and requires bifurcation and liability classification, at fair value. The fair value of the derivative liability as of the date of issuance was $521,383 and was recorded as a discount of the Notes. In August 2020, this note was fully converted into common stock leaving no balance as of October 31, 2020. In December 2019, the Company entered into Securities Purchase Agreements with an investor pursuant to which the Company sold a convertible note bearing interest of 12% per annum in the principal amount of $2,200,000 and due in 18 months. The purchase price of the note was $2,000,000 and the remaining $200,000 of principal amount represents original issue discount. Subject to certain ownership limitations, the note is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of 95% of the lowest stock five trading days prior to conversion less. During the 2020 fiscal year, the Company defaulted on the note for not filing the S-1 within a required period. Thereafter the interest increased to 22% per annum and the conversion price decreased to 85% of the lowest stock five trading days prior to conversion. The embedded beneficial conversion feature in the note meets the definition of a derivative and requires bifurcation and liability classification, at fair value. The fair value of the derivative liability as of the date of issuance was $111,508 and was recorded as a discount of the note. On February 18, 2020, the investor has filed suit and the Company is evaluating the claim and has had a preliminary settlement discussion with the plaintiff. In November 2019, the Company entered into Securities Purchase Agreements pursuant to which the Company sold convertible notes bearing 10% interest per annum (the “Notes”) in the aggregate principal amount of $203,333. The purchase price of the note was $183,333 and the remaining $20,000 of principal amount represents original issue discount. Subject to certain ownership limitations, the Notes are convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of 80% of the lowest 20 days prior to conversion. The embedded beneficial conversion feature of these notes meets the definition of a derivative and requires bifurcation and liability classification, at fair value. The fair value of the derivative liability as of the date of issuance was $161,325 and was recorded as a discount of the notes. On February 10, 2020, the Company entered into a Securities Purchase Agreement with an investor pursuant to which the Company sold a convertible note bearing interest at 12% per year in the principal amount of $305,000 and issued 35,000 shares of common stock. The purchase price of the note was $270,000 and the remaining $35,000 of principal amount represents $30,000 of original issue discount and $5,000 of closing costs. Subject to certain ownership limitations, the note is convertible at the option of the holder at any time into shares of our common stock at an effective conversion price equal to 80% of the lowest closing price as of the date of the notice. The embedded beneficial conversion feature of these note meets the definition of a derivative and requires bifurcation and liability classification, at fair value. The fair value of the derivative liability as of the date of issuance was $131,703 and was recorded as a discount of the note. During the three months ended October 31, 2020, the entire note was converted into common stock. On February 19, 2020, a lender made a formal demand for repayment of a note payable due on August 29, 2020 because they claim Company failed to comply with all terms of the note. On April 8, 2020, the Company signed a forbearance agreement with the lender to remove the major default penalty but increase the annual interest rate to 22%. The balance of the note was amended to $956,535 in cash which includes principal in the amount of $772,500 and approximately $184,035 of accrued interest and penalties. On July 31, 2020, a settlement was reached where the Company agreed to issue 3,499,415 shares of common stock for $1,459,676 which included $772,500 of principal and $687,176 of interest and penalties. On July 30, 2020, the note was settled to be paid in Company common stock and on August 11, 2020, the shares were issued. As of October 31, 2020, there were two notes in default with an aggregate principal balance of $2,882,000. The notes are accruing at default rates of interest of 22% and 24% per annum. On February 28, 2020, the Company entered into a series of Securities Purchase Agreements with three investors pursuant to which the Company agreed to sell and sold convertible notes bearing interest at 9.5% per year in the aggregate principal amount of $281,600. The purchase price of the notes in the aggregate was $250,000 and the remaining $31,600 of principal amount represents original issue discount. Subject to certain ownership limitations, the notes will be convertible at the option of the holder at any time into shares of our common stock at an effective conversion price equal 80% of the lowest closing price for the ten trading days prior to the day of the notice. The embedded beneficial conversion feature of these notes meets the definition of a derivative and requires bifurcation and liability classification, at fair value. The fair value of the derivative liability as of the date of issuance was $128,219 and was recorded as a discount of the notes. On April 9, 2020, the Company issued a note to a lender for $50,000 due in year with an interest rate of 10% per annum. The funds were paid directly to one of the Company’s vendors. On May 4, 2020, the Company issued a promissory note with a purchase price of $100,000 to the same investor that matures in one year and has a stated interest rate of 10% per annum. Additionally, the Company agreed to issue 20,000 shares of restricted common stock and 20,000 stock options with an exercise price of $0.43 which was due upon execution of the note. On October 9, 2020, the Company paid $60,000 toward these notes leaving a balance of $90,000 as of October 31, 2020. In April 2020, Regentys, Olaregen, NDS 2 and MediSource (collectively “the Subsidiaries”) were granted loans (the “PPP Loans”) in the aggregate amount of $499,473, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act, which was enacted March 27, 2020. The application for these funds required the Company to, in good faith, certify that the current economic uncertainty made the loan request necessary to support the ongoing operations of the Company. This certification further required the Subsidiaries to consider its current business activity and its ability to access other sources of liquidity sufficient to support ongoing operations in a manner that is not significantly detrimental to the business. The receipt of these funds, and the forgiveness of the loan attendant to these funds, is dependent on the Subsidiaries having initially qualified for the loan and qualifying for the forgiveness of such loan based on its future adherence to the forgiveness criteria. The PPP Loans, which were in the form of a notes with dates ranging between April 17 and April 24, 2020 and mature between two and five years and bear interest at a rate of 1.00% per annum, payable in monthly payments commencing six months after loan disbursements. The notes may be prepaid by the Subsidiaries at any time prior to maturity with no prepayment penalties. Funds from the PPP Loan may only be used for payroll costs and any payments of certain covered interest, lease and utility payments. Under the terms of the PPP, certain amounts of the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. No assurance can be provided that the Company will obtain forgiveness of the PPP Loan in whole or in part. On June 25, 2020, the Company entered into a Securities Purchase Agreements pursuant to which the Company sold a convertible note bearing interest at 12% per year in the principal amount of $150,000. The purchase price of the note was $145,000 and the remaining $5,000 of principal represents original issue discount. Subject to certain ownership limitations, the notes will be convertible at the option of the holder at any time into shares of our common stock at an effective conversion price equal 80% of the lowest closing price for the ten trading days prior to the day of the notice. The embedded beneficial conversion feature of these Notes meets the definition of a derivative and requires bifurcation and liability classification, at fair value. The fair value of the derivative liability as of the date of issuance was $59,985 and was recorded as a discount of the note. During September 2020 and October 2020, the entire note was converted into common stock. Amount Balance of notes payable on July 31, 2020 $ 11,166,359 Increase in debt due to default 255,080 Amortization of debt discount 174,049 Conversions (1,077,086 ) Payments (60,000 ) Balance of notes payable on October 31, 2020 $ 10,458,402 As of October 31, 2020 As of July 31, 2020 Notes payable $ 10,709,655 $ 11,591,661 Less: debt discount (251,253 ) (425,302 ) Total debt, net of discount 10,458,402 11,166,359 Notes payable, net - noncurrent 499,839 499,656 Notes payable, net - current $ 9,958,563 $ 10,666,703 On December 28, 2017, the Company through its then wholly owned subsidiary NuGenerex Distribution Solutions, LLC (“NuGenerex”), completed the acquisition of the assets and 100% of the membership interests of two pre-operational pharmacies, Empire State Pharmacy, LLC (“Empire Pharmacy”) and Grainland Pharmacy, LLC (“Grainland Pharmacy”), pursuant to the bills of sale for a consideration of $320,000 Promissory Note due and payable in full on June 28, 2018 bearing an annual interest rate of 3%. The note was extended by six months and set to mature with the same terms on December 28, 2018. The note remains active and interest has continued to accrue while new terms of the note are in process of being negotiated. Empire Pharmacy is not currently operating, and Grainland Pharmacy has been dissolved. Pursuant to the second closing of the acquisition of certain operating assets of Veneto Holdings, L.L.C. and its affiliates, Generex’s wholly owned subsidiary agreed to assume outstanding debt of Veneto subsidiaries to Compass Bank, including obligations under a term loan and a revolving line of credit. Claiming three separate types of default, Compass Bank has demanded payment in full of amounts due under the term loan and revolving line of credit, in an aggregate amount of approximately $3,413,000. Generex believes it has defenses to such demand, including that the bank was not an intended beneficiary of the subsidiary’s agreement to assume the debt. Pursuant to its acquisition of Regentys, the Company inherited convertible notes with several investors which collectively held a principal plus of $615,000 as of the date of acquisition. As of October 31, 2020, the remaining principal balance was $349,656 with an unamortized debt discount balance of $16,824. These notes have an accrued interest balance of $95,885 as of October 31, 2020.

Derivative Liability

Derivative Liability	3 Months Ended
	Oct. 31, 2020
Notes to Financial Statements
Derivative Liability	Note 8 – Derivative Liability The Company issued debts that consist of the issuance of convertible notes with variable conversion provisions. The conversion terms of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock. The number of shares of common stock to be issued is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the promissory note is indeterminate. Due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit, the equity environment is tainted, and all additional convertible debentures and warrants are included in the value of the derivative liabilities. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the variable conversion options and warrants and shares to be issued were recorded as derivative liabilities on the issuance date and revalued at each reporting period. Based on the various convertible notes described in Note 7, and the sale of common stock in a private investment in public equity (“PIPE”) described in Note 9, the fair value of applicable derivative liabilities on notes, warrants and change in fair value of derivative liability are as follows as of October 31, 2020: Derivative Liability - Convertible Notes Derivative Liability - Warrants Total Balance as of July 31, 2020 $ 742,391 $ 574,366 $ 1,316,757 Additions during the period — 21,574,216 21,574,216 Change in fair value 111,150 (4,131,002 ) (4,019,852 ) Change due to conversion / exercise (538,084 ) (1,840,530 ) (2,378,614 ) Balance as of October 31, 2020 $ 315,457 $ 16,177,050 $ 16,492,507

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Oct. 31, 2020
Equity [Abstract]
Stockholders' Equity	Note 9 - Stockholders’ Equity Common Stock Stock compensation expense During the three months ended October 31, 2020, the Company recognized $1,210,859 of expense related to the vesting of stock options. In October 2020, the Company issued 51,130 shares of common stock to vendors for services valued at $0.215 per share, or $10,993. Sale of common stock On November 25, 2019, the Company entered an Equity Purchase Agreement with Oasis Capital, LLC (“Oasis”) to purchase up to $40,000,000 of the Company’s stock at 92% of the market price for the period of five (5) consecutive trading days immediately subject to a put notice on such date on which the Purchase Price is calculated in accordance with the terms and conditions of the agreement (subject to certain limitations) from time to time over a 36-month period. During September 2020 and October 2020, Oasis purchased 2,100,000 shares of common stock in three tranches for an aggregate price of $356,710. Issuance of common stock in a PIPE deal, net of fees and exercise of warrants On August 4, 2020, the Company and three institutional accredited investors (each a “Buyer” and, collectively, the “Buyers”) entered into a securities purchase agreement pursuant to which the Company sold and issued to the Buyers an aggregate of 5,102,040 shares of the Company’s common stock, par value $0.001 per share, and received net proceeds of $1,850,000 after deducting commissions and attorney’s fees of $150,000. Pursuant to the Securities Purchase Agreement, the Company issued to the Buyers (i) Series A Warrants to purchase 5,102,040 shares of Common Stock in the aggregate (the “Series A Warrants”) with an initial exercise price equal to $0.392 per share (the “Series A/B Exercise Price”), (ii) Series B Warrants to purchase 15,306,122 shares of Common Stock in the aggregate (the “Series B Warrants”) with an initial exercise price equal to the Series A/B Exercise Price; (iii) Series C Warrants to purchase the number of shares of Common Stock equal to Maximum Eligibility Number (as defined therein) (the “Series C Warrants”) at an initial exercise price equal to $0.539 per share; and (iv) Series D Warrants to purchase the number of shares Common Stock equal to the Maximum Eligibility Number (as defined therein) (the “Series D Warrants” and together with the Series A Warrants, the Series B Warrants and the Series C Warrants, the “Warrants” and the Warrants together with the Common Shares and the shares of Common Stock underlying the Warrants, the “Securities”) at an exercise price equal to $0.001 per share, in each case, subject to adjustment and beneficial ownership limitations set forth therein. Subject to the satisfaction or waiver of certain conditions set forth in the Series A Warrants, the Company may force the Buyers to exercise the Series A Warrants in full on the twenty second (22nd) trading day (the “Forced Exercise Date”) after the effectiveness of the Company’s registration statement that registers all of the Common Shares and shares underlying the Warrants. The exercise price set forth in each of the Series A Warrants, the Series B Warrants and Series C Warrants is subject to adjustment on certain trigger dates as provided in each such Warrant. The holders of the Series A Warrants, Series B Warrants and Series C Warrants shall be allowed a cashless exercise if a registration statement registering the Securities is not effective within 180 days following the issuance of such Warrants. On certain interim reset dates (“Interim Reset Date(s)” and second trigger dates (“Second Trigger Date(s)”) as set forth in the Series D Warrants, the Series D Warrants will become exercisable into a number of shares of Common Stock that would have been issued on the issuance date and upon exercise of the Series A Warrants and Series B Warrants had the purchase price per share and exercise price of the Series A Warrants and Series B Warrants been equal to the applicable reset price as set forth in the Series D Warrant; or the right to use the applicable exercise price, or adjustment right (as the case may be) calculated using the Black-Scholes Option Pricing Model pursuant to the Securities Purchase Agreement. The Buyers have the potential right to have these Warrants settled in cash equal to the Black Scholes value of any remaining unexercised warrant. As a result, of an Interim Reset Date on September 28, 2020, and Second Trigger Date on October 12, 2020, the additional warrants were issued and the exercise price adjusted as follows: (i) 5,112,463 additional Series A Warrants were issued to purchase 10,214,503 in the aggregate shares of Common Stock with a “reset” exercise price equal to $0.1958 per share (the “Series A/B Reset Exercise Price”), (ii) 15,337,389 additional Series B Warrants to purchase 30,643,509 shares of Common Stock in the aggregate with a reset exercise price equal to the Series A/B Exercise Price; (iii) 9,142,973 additional Series C Warrants to purchase the number of shares of Common Stock to purchase 19,347,053 shares of Common Stock in the aggregate at a reset exercise price equal to $0.28149 per share; and (iv) the Buyers exercised 9,142,973 Series D Warrants and purchased 9,142,973 shares of Common Stock at $0.001 per share (See Note 12 – Warrants). Deemed dividend related to issuance of warrants containing derivative liabilities As a result of the excess warrant liability recorded relative to the total proceeds received in connection with the Securities Purchase Agreement (see Note 8), this led to a full discount ascribed to the common stock. Accordingly, the Company then immediately recorded a deemed dividend of $1,850,000 to accrete the common stock to the value received in this transaction by increasing Additional Paid-in Capital and reducing accumulated deficit by $1,850,000. As a result of the excess warrant liability for the warrants granted relative to total proceeds received in connection with pursuant to the Securities Purchase Agreement (see Note 8) it was determined to be immediately beneficial upon initial closing date and, as a result, the Company recorded a deemed dividend of $1,850,000 increasing Additional Paid-in Capital and reducing the Accumulated Deficit by $1,850,000. Issuance of common stock payable During the three months ended October 31, 2020 and 2019, 3,529,415 and 296,793 shares of common stock payable were issued to settle outstanding obligations, valued at $1,472,826 and $921,895, respectively. As of October 31, 2020 and July 31, 2020, the value of the remaining shares to be issued was $8,483,393 and $10,079,449, respectively. Common Stock Payable Balance as of July 31, 2020 $ 10,079,449 Issuance of common stock payable (1,472,826 ) Change in fair value of common stock payable (123,230 ) Balance as of October 31, 2020 $ 8,483,393 Conversion of debt to equity During the three months ended October 31, 2020 and 2019, the Company issued 5,860,255 and 1,164,190 shares of common stock for the conversion of $1,127,842 and $1,736,837 of debt, respectively. As a result of the debt conversions during the three months ended October 31, 2020 and 2019, $538,084 and $1,911,487 of derivative liabilities were reduced, respectively. Issuance of common stock for acquisitions In August 2019, the Company issued 400,000 and 560,000 shares of common stock valued at $2.50 per share for the acquisition of MediSource and Pantheon, respectively. Cancellation of shares On September 12, 2019, 20,375,900 outstanding shares of common stock were cancelled by the Company held by Joe Moscato TTEE Friends of Generex Biotechnology Investment Trust U/A/D 4/2/2019, a trust formed for the benefit the Company and any 80% controlled subsidiary of the Company by several shareholders contributing in the aggregate 33,175,900 shares of the Company’s Common Stock and 8,293,975 shares of NGIO commons shares (the “Friends of Generex Trust”), similar to the Stock Control Agreement previously entered into by the same shareholders on December 1, 2018 filed in an 8-K filed on December 3, 2019, incorporated herein by reference. Non-controlling Interest Regentys Pursuant to the Company’s acquisition of Regentys on January 7, 2019 to acquire a 51% interest, the Company was issued 12,048,161 shares of Regentys common stock. As of January 31, 2020, Regentys had a total of 18,623,278 shares of common stock and 2,793,192 Series A voting preferred stock for a total of 21,416,470 total voting shares outstanding. As such, there are 9,368,309 of shares that belong to non-controlling interest shareholders which represents a 43.74% non-controlling interest. Olaregen Pursuant to the Company’s acquisition of Olaregen on January 7, 2019 to acquire a 51% interest, the Company was issued 3,282,632 shares of Olaregen common stock from Olaregen shareholders. In May 2019, the Company issued 4,000,000 shares of common stock contributed and provided by the Friends of Generex Trust and a $2 million note payable for the acquisition of 592,683 shares of Series A Preferred Stock of Olaregen pursuant to a Stock Purchase Agreement entered into January 14, 2019 subject to the approval of the Board of Directors of Olaregen and consummated on May 10, 2019. The provided shares by the Friends of Generex Trust were already issued and outstanding and did not result in any expense of the Company. Since these shares were transferred, to the shareholders of Olaregen, by an existing shareholder to settle an obligation of the Company, the value of the shares provided by the Friends of the Generex Trust to settle the debt was reflected in the financial statements as an addition to contributed (paid-in) capital. On February 14, 2020, the remaining stockholders of Olaregen exchanged all of its outstanding shares for 5,950,000 shares of Generex common stock and 2,765,000 shares of NGIO. After this transaction Olaregen became a 100% owned subsidiary. Veneto On November 1, 2018, the Company completed its second closing of Veneto Holdings, L.L.C. (“Veneto”) which granted the Company Rapport Services, LLC (“Rapport”) through the ownership of the units of Class B membership interests providing control of Rapport as only the Class B Member is entitled to elect the nominees to the Board of Managers, which constitute a one percent (1%) ownership in Rapport. The remaining interests represent a 99% non-controlling interest. NuGenerex Immuno-Oncology, Inc. On July 14, 2020, NGIO entered into a purchase agreement with an investor Oasis Capital, LLC (“Oasis”) pursuant to which Oasis has agreed to purchase from the Company up to $50,000,000 of common stock at 92% of the market price for the period of five (5) consecutive trading days immediately subject to a put notice on such date on which the purchase price is calculated in accordance with the terms and conditions of the agreement (subject to certain limitations) from time to time over a 36-month period. NGIO also issued to Oasis 300,000 shares of its common stock under the Oasis Capital Agreement as a commitment fee in connection with a registration statement. This transfer has been accounted through common stock and additional paid in capital which has no net effect on equity. As of October 31, 2020, 400,300,000 shares of NGIO are issued and outstanding of which 36,296,849 shares belong to non-controlling interest shareholders which represents a 9.07% non-controlling interest.

Redeemable Non-Controlling Inte

Redeemable Non-Controlling Interest	3 Months Ended
	Oct. 31, 2020
Notes to Financial Statements
Redeemable Non-Controlling Interest	Note 10 – Redeemable Non-Controlling Interest Pursuant to the Company’s acquisition of 51% of the outstanding capital stock of Regentys, Regentys had authorized 7,500,000 shares of redeemable Series A Convertible Preferred Stock (“Preferred Stock A”), with a par value of $0.0001 and redemption value of $0.65 per share of which 2,793,192 Preferred Stock A was outstanding as of the date of acquisition and as of January 31, 2020. Preferred Stock may be converted into common stock at the initial conversion ratio of 1:1 which ratio shall be adjusted in accordance with stock dividends, splits, combinations and other similar events, including the sale of additional shares of common or preferred stock and the holders of Preferred Stock A are entitled to vote, together with the holders of Regentys common stock, on all matters submitted to stockholders of Regentys for a vote. At any time after November 1, 2026, the holders of the Company’s Series A Preferred Stock will have the right to require the Company to redeem all or a portion of their shares for cash at a redemption price equal to its liquidation value. Accordingly, this Preferred Stock A was valued to be $4,073,898 at the time of acquisition of Regentys and reclassified as Redeemable Non-Controlling Interest outside of stockholders’ deficit on the consolidated balance sheets.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Oct. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 11 - Stock-Based Compensation Stock Option Plans The Company has two stockholder-approved stock incentive plans under which shares and options exercisable, with a range of vesting between 0 and 48 months, for shares of common stock have been or may be granted to employees, directors, consultants and advisors. All remaining options under the 2006 Stock Plan have expired and no shares of common stock are reserved for issuance under the 2006 Stock Plan as amended (the 2006 Plan) and a total of 240,000,000 shares of common stock reserved for issuance under the 2017 Stock Option Plan (the 2017 Plan). As of October 31, 2020, there were 0 and 229,077,640 shares available under the 2006 Plan and 2017 Plan, respectively. The Company issues new shares of common stock from the shares reserved under the respective Plans upon conversion or exercise of options and issuance of restricted shares. During 2019, the Company established a Direct Stock Purchase Plan (“2019 Plan”) pursuant to which eligible participants may acquire shares of common stock in lieu of certain cash obligations otherwise owed to participants during the 2019 calendar year. The 2019 Plan automatically terminated on December 31, 2019. There was a total of 1,680,000 shares of common stock reserved under the plan of which no shares have been issued. The 2017 Plan (the Plan) is administered by the Board of Directors (the Board). The Board is authorized to select from among eligible employees, directors, advisors and consultants those individuals to whom options are to be granted and to determine the number of shares to be subject to, and the terms and conditions of the options. The Board is also authorized to prescribe, amend and rescind terms relating to options granted under the Plan. Generally, the interpretation and construction of any provision of the Plan or any options granted hereunder is within the discretion of the Board. The Plans provide that options may or may not be Incentive Stock Options (ISOs) within the meaning of Section 422 of the Internal Revenue Code. Only employees of the Company are eligible to receive ISOs, while employees and non-employee directors, advisors and consultants are eligible to receive options which are not ISOs, i.e. “Non-Qualified Options.” The options granted by the Board in connection with its adoption of the Plans were Non-Qualified Options. In addition, the 2006 Plan also provides for restricted stock grants. The fair value of each option granted is estimated on the grant date using the Black-Scholes option pricing model or the value of the services provided, whichever is more readily determinable. The Black-Scholes option pricing model takes into account, as of the grant date, the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk-free interest rate for the term of the option. During August and September 2020, the Company granted 6,222,210 stock options to buy common stock, at $0.45 per share and $0.31 per share, to various officers, board members, employees and consultants. The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan: Options Weighted Average Exercise Price per Share Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Outstanding - July 31, 2020 8,847,025 $ 0.90 5.96 $ 508,932 Granted 6,222,210 $ 0.35 9.84 — Forfeited or expired (2,146,875 ) $ 0.82 6.75 — Exercised — — — — Outstanding – October 31, 2020 12,922,360 $ 0.65 7.52 $ 130,315 The intrinsic value is calculated as the difference between the market value and the exercise price of the shares on October 31, 2020. The market value was $0.208 based on the closing bid price for October 31, 2020. A summary of the status of the Company’s non-vested stock options the three months ended October 31, 2020 is as follows: Non-vested Options Options Weighted Average Grant Date Fair Value Non-vested on July 31, 2020 4,082,767 $ 1.06 Granted 6,222,210 0.35 Expired — — Canceled (366,667 ) 0.79 Vested (2,459,053 ) 0.59 Non-vested on October 31, 2020 7,479,257 $ 0.64 There were 5,443,103 vested common stock options under the Plan as of October 31, 2020. The compensation expense was $1,211,007 for the three months ended October 31, 2020. The Company had $3,936,129 of unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the Plan on October 31, 2020 to be recognized over an average of 2.09 years. The Company estimated the fair value of each stock option on the grant date using a Black-Scholes option-pricing model. Black-Scholes option-pricing models requires the Company to make predictive assumptions regarding future stock price volatility, recipient exercise behavior, and dividend yield. The Company estimated the future stock price volatility using the historical volatility over the expected term of the option. The following assumptions were used in the Black-Scholes option-pricing model: October 31, 2020 Exercise price $0.31 – $0.45 Time to expiration 10 years Risk-free interest rate 0.16% - 0.18 % Estimated volatility 148.3% - 148.8 % Expected dividend — Stock price at valuation date $0.31 – $0.45

Warrants

Warrants	3 Months Ended
	Oct. 31, 2020
Warrants Abstract
Warrants	Note 12 - Warrants As of July 31, 2020, the Company had 567,553 warrants outstanding. On August 4, 2020, the Company initially issued 30,612,240 warrants in the aggregate pursuant to the Private Placement (see Note 9 - Stockholders’ Equity, Sale of common stock in a private placement (PIPE), net of fees and exercise of warrants); The following is a table of warrants issued in connection with the PIPE deal during the three months ended October 31, 2020: Initial Exercise Price Initial Warrants Issued Additional Warrants Issued Reset Exercise Price Outstanding Warrants as of October 31, 2020 Series A Warrants $ 0.392 5,102,040 5,112,463 $ 0.196 10,214,503 Series B Warrants $ 0.392 15,306,120 15,337,389 $ 0.196 30,643,509 Series C Warrants $ 0.539 10,204,080 9,142,973 $ 0.281 19,347,053 Total Warrants from PIPE deal 30,612,240 29,592,825 60,205,065 On September 28, 2020, the Interim Reset Date, 5,662,190 Series D Warrants were issued and exercised at $0.001 per share; and on October 12, 2020, the Second Trigger Date on October 12, 2020, 3,480,783 Series D Warrants were issued and exercised at $0.001 per share, for an aggregate of 9,142,973 warrants issued and exercised. A summary of the Company’s warrant activities is as follows: Number of Warrants Weighted Average Exercise Price per Share Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Outstanding - July 31, 2020 567,553 $ 2,50 2.20 $ — Issued 69,348,038 0.19 5 7,546,985 Exercised (9,142,973 ) 0.001 5 1,892,595 Expired — — — — Outstanding – October 31, 2020 60,772,618 $ 0.24 4.99 $ 5,654,389

Net Income Per Share (EPS)

Net Income Per Share (EPS)	3 Months Ended
	Oct. 31, 2020
Accounting Policies [Abstract]
Net Income Per Share (EPS)	Note 13 - Net Income Per Share (“EPS”): Basic net income or loss per share is calculated using the weighted average number of common shares outstanding during the period. Diluted earnings per common share is the same as basic earnings per common share because, as the Company incurred a net loss during each period presented, the potentially dilutive securities from the assumed exercise of all outstanding stock options, warrants and conversion notes payables, would have an anti-dilutive effect. The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common shareholders because including them would have been anti-dilutive for the years ended October 31, 2020 and 2019, respectively. Three Months Ended October 31, 2020 2019 Convertible debt 16,867,885 5,061,647 Stock options 12,922,360 9,339,195 Warrants 60,772,618 21,567,553 Total 90,562,863 35,968,395

Income Taxes

Income Taxes	3 Months Ended
	Oct. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Note 14 – Income Taxes: The Company has incurred losses since inception, which have generated net operating loss (“NOL”) carryforwards. The NOL carryforwards arise from both United States and Canadian sources. Pre-tax loss arising from domestic operations (United States) were $10,982,942 and $34,291,142 for the three months ended October 31, 2020 and the year ended July 31, 20120, respectively. Pre-tax (losses)/income arising from foreign operations (Canada) were ($6,134) and $59,049 for the three months ended October 31, 2020 and the year ended July 31, 2020, respectively. As of October 31, 2020, the Company has NOL carryforwards in Generex Biotechnology Corporation of approximately $219.7 million, of which $189.5 million will expire in 2021 through 2038, and $30.3 million will not expire. Generex Pharmaceuticals Inc. has NOL carryforwards of approximately $34.4 million, which expire in 2026 through 2041. NGIO has NOL carryforwards of approximately $35.7 which will expire in 2021 through 2038. Regentys Corporation has NOL carryforwards of approximately $6.6 million, of which $5.0 million will expire in 2033 through 2038 and $1.6 million will not expire. Olaregen Therapeutics, Inc. has NOL carryforwards of $4.1 million which will not expire. Veneto has NOL carryforwards of $10.6 million which will not expire. Some of these loss carryforwards are subject to limitation due to the acquisition of Regentys, Olaregen and NGIO and may be limited in future years due to certain structural ownership changes which have occurred over the last several years related to the Company’s equity and convertible debenture financing transactions. As of October 31, 2020, the Company had no tax benefits which have not been fully allowed for, and no adjustment to its financial position, results of operations or cash flows was required. The Company has deferred tax assets of over $73 million with a full allowance equal to the to the amount of the deferred tax asset. The Company does not expect that unrecognized tax benefits will increase within the next twelve months. The Company records interest and penalties related to tax matters within other expense on the accompanying consolidated statement of operations. These amounts are not material to the consolidated financial statements for the years presented. Generally, tax years 2017 to 2020 remain open to examination by the Internal Revenue Agency or other tax jurisdictions to which the Company is subject. The Company’s Canadian tax returns are subject to examination by federal and provincial taxing authorities in Canada. Generally, tax years 2012 to 2020 remain open to examination by the Canada Revenue Agency or other tax jurisdictions to which the Company is subject. On March 27, 2020, the CARES Act was enacted and signed into law in the U.S. in response to the COVID-19 pandemic. One of the provisions of this law is the temporary suspension of the 80% limitation on the utilization of net operating losses generated in taxable years beginning after December 31, 2017 and before January 1, 2021. Additionally, the CARES Act allows The Company to carryback net operating losses generated in taxable years beginning after December 31, 2017 and before January 1, 2021 to the five previous periods if the company has taxable income in the carryback years. Neither of these modifications are expected to apply to the Company due to the sustained history of losses.

Subsequent Events

Subsequent Events	3 Months Ended
	Oct. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 15 - Subsequent Events: The Company has evaluated subsequent events occurring after the balance sheet date through the date the unaudited condensed interim consolidated financial statements were issued. On November 9, 2020 and November 18, 2020, the Company exercised put options pursuant to an Equity Purchase Agreement with Oasis for an aggregate of 1,750,000 shares of Generex common stock for $306,939 of net proceeds. On November 13, 2020, Generex Biotechnology Corporation and its majority owned subsidiary NuGenerex Immuno-Oncology, Inc., (collectively “Generex”) signed The Ii-Key Innovative Vaccine Development Agreement (the “Agreement”) with Beijing Youfeng International Consulting Co., Ltd (“BYIC”), National Institute for Viral Disease Control and Prevention, Chinese Centre for Disease Control and Prevention (“NIVDC”) and Beijing Guoxin Haixiang Equity Investment Partnership (“BGHEIP” and together with BYIC and NIVDC, the “China Partners”) to set up a joint research team and a joint entity in China (the “Joint Entity”) that shall jointly develop and industrialize the Generex internationally patented Ii-Key innovative technology for a SARS-CoV-2 coronavirus peptide vaccine (the “Vaccine”) and other vaccines in the People’s Republic of China (“China”) and for Generex to provide the Joint Entity with an exclusive license to use its intellectual property; technical know-how, pre-clinical and clinical data and background materials, in each case, relating to Ii-Key-SARS-CoV-2 technology in the People’s Republic of China, including Hong Kong Special Administrative Region and Macau Special Administrative Region, but excluding the Islands of Taiwan (the “Licensed Territory”). The Agreement, among other things, consists of the Joint Entity providing 100% funding for the clinical development, manufacturing and commercial registration of the Vaccine for China and paying Generex licensing and royalty fees as follows: 1. Licensing Fee: $5,000,000 upfront fee due upon the execution of the Agreement; and then upon a successfully approved Vaccine, and an additional $20,000,000 from the net profits from the Joint Entity. 2. Royalty Fee: Once the Vaccine comes on to market for the first commercial sale, then the Joint Entity shall: a. Offer Generex 20% of the equity interests in the Joint Entity; or b. Cash payments to Generex in a price equal to $2 per dose for the COVID-19 vaccine. The Joint Entity shall have the perpetual sole and exclusive license to use the Generex technology within Licensed Territory. Generex shall negotiate separately with the Joint Entity with respect to the sale of such technology in other countries outside the Licensed Territory. On November 13, 2020, Generex Biotechnology Corporation and its majority owned subsidiary NuGenerex Immuno-Oncology, Inc., (collectively “Generex”) signed The Ii-Key Innovative Flu Vaccine Development Agreement (the “Agreement”) with Beijing Youfeng International Consulting Co., Ltd, National Institute for Viral Disease Control and Prevention, Chinese Centre for Disease Control and Prevention (NIVDC) and Beijing Guoxin Haixiang Equity Investment Partnership (Limited Partnership) (collectively referred to as “China Partners”) to set up a joint entity in China (the “Joint Entity”) that shall jointly develop and industrialize the Generex internationally patented Ii-Key innovative technology for a Flu peptide vaccine and other vaccines (the “Vaccine”) in the People’s Republic of China (“China”). The Agreement, among other things, consists of the Joint Entity providing 100% funding for the clinical development, manufacturing and commercial registration of the Vaccine for China and paying Generex a licensing fee of US$2,500,000 (minus expenses estimated at US$500,000) upon successful development of the flu vaccine and receipt of approval from NMPA for the product launch. The Joint Entity shall have the perpetual sole and exclusive license to use the Generex technology within licensed territory and the licensed area. On November 17, 2020, Generex signed statement of work (SOW) #2 with CTL to conduct FDA requested laboratory testing and analysis for a contracted amount of $82,780. On November 19, 2020 Generex signed a work order with Polypeptide Laboratories to manufacture GMP grade Ii-Key vaccines for the COVID-19 vaccine program for a contracted amount of $273,000. On November 25, 2020 Generex signed a work order with Covance to conduct preclinical animal immunogenicity studies for the Ii-Key COVID-19 vaccine program. The cost of the project is projected at $130,135. On December 7, 2020, Generex signed a contract with Patheon, by Thermo Fisher Scientific, to provide manufacturing and fill/finish services for the clinical supply of aseptically filled Ii-Key-SARS COV2 Vaccine Sterile Liquid Vials (the “Product”) for a Phase I/II study. The cost of the project, specifications for which are still in development, are expected to be in the range of $1,127,000 and $1,530,000.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Oct. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments, considered necessary for a fair presentation have been included. The Company’s fiscal year ends on July 31 of each calendar year. Each reference below to a fiscal year refers to the fiscal year ending in the calendar year indicated. Operating results for the three months ended October 31, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2021. The balance sheet on October 31, 2020 does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Therefore, these condensed financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended July 31, 2020 as filed with the U.S. Securities and Exchange Commission (“SEC”).
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from those estimates.
Business Combinations	Business Combinations Business combinations are accounted for using the acquisition method of accounting. Acquisition cost is measured as the aggregate of the fair value at the date of acquisition of the assets given, equity instruments issued, or liabilities incurred or assumed. Acquisition related costs are expensed as incurred (except for those costs arising on the issue of equity instruments which are recognized directly in equity). Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured at fair value on the acquisition date. Goodwill is measured as the excess of the acquisition cost and the amount of any non-controlling interest, over the fair value of the identifiable net assets acquired.
Revenue Recognition	Revenue Recognition It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 “Revenue Recognition.” Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Revenue from NGDx is recognized upon payment at the time the product(s) is released (shipment delivered using a common carrier), and the control is transferred which is simultaneous to when payment received and accepted. Revenue from product sales of Olaregen’s Excellagen® is recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government rebates. Revenue from product sales of Pantheon medical surgical kits used in surgical procedures is recorded all revenue is recognized at a point in time, generally when title of the product and control is transferred to the client which occurs upon the completion of surgical procedure when the product utilized and the medical facility provides a final list of products consumed. The Company constrains revenue by considering factors that could otherwise lead to a probable reversal of revenue. Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as the Company’s historical experience, contractual arrangement and specific known market events and trends. Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers. Revenue from the provision of management services is recognized in accordance with the contractual terms of the relationship (item i); however, the current agreements in place typically specify that a percentage of the gross margin associated with the third-parties’ sales that the Company facilitates is to be remitted (iii), and as such, the revenue is considered earned upon completion of the third parties’ sales of such products (iv). Three months ended October 31, Revenue Source 2020 2019 Product sales $ 88,435 $ 713,405 Management services — 8,256 Total Revenue $ 88,435 $ 721,661 Provisions for estimated sales returns and uncollectible accounts are recorded in the period in which the related sales are recognized based on historical and anticipated rates.
Adoption of New Accounting Standards	Adoption of New Accounting Standards In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment
Recently Issued Accounting Standards	Recently Issued Accounting Standards In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, and ASU 2019-05 (collectively, “Topic 326”). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. The Company will be required to adopt this ASU for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The adoption of Topic 326 is not expected to have a material on the Company’s consolidated financial statements and financial statement disclosures. In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Company. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Oct. 31, 2020
Accounting Policies [Abstract]
Schedule of revenue recognized	Three months ended October 31, Revenue Source 2020 2019 Product sales $ 88,435 $ 713,405 Management services — 8,256 Total Revenue $ 88,435 $ 721,661

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Oct. 31, 2020
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consists of the following components: October 31, July 31, 2020 2020 Raw materials $ 182,722 $ 182,722 Finished goods 535,902 559,534 Total Inventory $ 718,624 $ 742,256

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Oct. 31, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment, net consisted of the following: October 31, July 31, 2020 2020 Computers and technological assets $ 50,205 $ 53,314 Machinery and equipment 317,751 329,977 Furniture and fixtures 18,725 18,725 Leasehold Improvements — 16,596 386,681 418,612 Less accumulated depreciation (211,168 ) (204,944 ) $ 175,513 $ 213,668

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Oct. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consist of the following at: Estimated October 31, July 31, Useful Lives 2020 2020 In-Process Research & Development $ 6,302,427 $ 6,302,427 Non-compete agreements 3 years 1,210,000 1,210,000 Developed software/technology 5 years 131,000 131,000 Intellectual Property 5 years 2,459,000 2,459,000 Patents 20 years 51,274 51,274 10,153,701 10,153,701 Less accumulated amortization (1,019,517 ) (788,175 ) $ 9,134,184 $ 9,365,526
Estimated amortization expense	The estimated amortization expense remainder of the current fiscal year and for the next five years and thereafter is as follows: Year Ending July 31, Amount For the nine months ended July 31, 2021 $ 692,555 2022 654,190 2023 520,564 2024 500,914 2025 458,202 Thereafter 5,332 Total $ 2,831,757

Notes Payable (Tables)

Notes Payable (Tables)	3 Months Ended
	Oct. 31, 2020
Debt Disclosure [Abstract]
Schedule of notes payable	During September 2020 and October 2020, the entire note was converted into common stock. Amount Balance of notes payable on July 31, 2020 $ 11,166,359 Increase in debt due to default 255,080 Amortization of debt discount 174,049 Conversions (1,077,086 ) Payments (60,000 ) Balance of notes payable on October 31, 2020 $ 10,458,402 As of October 31, 2020 As of July 31, 2020 Notes payable $ 10,709,655 $ 11,591,661 Less: debt discount (251,253 ) (425,302 ) Total debt, net of discount 10,458,402 11,166,359 Notes payable, net - noncurrent 499,839 499,656 Notes payable, net - current $ 9,958,563 $ 10,666,703

Derivative Liability (Tables)

Derivative Liability (Tables)	3 Months Ended
	Oct. 31, 2020
Notes to Financial Statements
Schedule of Derivative Liabilities at Fair Value	Based on the various convertible notes described in Note 7, and the sale of common stock in a private investment in public equity (“PIPE”) described in Note 9, the fair value of applicable derivative liabilities on notes, warrants and change in fair value of derivative liability are as follows as of October 31, 2020: Derivative Liability - Convertible Notes Derivative Liability - Warrants Total Balance as of July 31, 2020 $ 742,391 $ 574,366 $ 1,316,757 Additions during the period — 21,574,216 21,574,216 Change in fair value 111,150 (4,131,002 ) (4,019,852 ) Change due to conversion / exercise (538,084 ) (1,840,530 ) (2,378,614 ) Balance as of October 31, 2020 $ 315,457 $ 16,177,050 $ 16,492,507

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Oct. 31, 2020
Equity [Abstract]
Schedule of Issuance of common stock payable	Common Stock Payable Balance as of July 31, 2020 $ 10,079,449 Issuance of common stock payable (1,472,826 ) Change in fair value of common stock payable (123,230 ) Balance as of October 31, 2020 $ 8,483,393

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Oct. 31, 2020
Share-based Payment Arrangement [Abstract]
Common stock options granted, forfeited or expired and exercised	The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan: Options Weighted Average Exercise Price per Share Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Outstanding - July 31, 2020 8,847,025 $ 0.90 5.96 $ 508,932 Granted 6,222,210 $ 0.35 9.84 — Forfeited or expired (2,146,875 ) $ 0.82 6.75 — Exercised — — — — Outstanding – October 31, 2020 12,922,360 $ 0.65 7.52 $ 130,315
Schedule of non-vested stock options	A summary of the status of the Company’s non-vested stock options the three months ended October 31, 2020 is as follows: Non-vested Options Options Weighted Average Grant Date Fair Value Non-vested on July 31, 2020 4,082,767 $ 1.06 Granted 6,222,210 0.35 Expired — — Canceled (366,667 ) 0.79 Vested (2,459,053 ) 0.59 Non-vested on October 31, 2020 7,479,257 $ 0.64
Fair value assumptions used in Black-Scholes option-pricing	The following assumptions were used in the Black-Scholes option-pricing model: October 31, 2020 Exercise price $0.31 – $0.45 Time to expiration 10 years Risk-free interest rate 0.16% - 0.18 % Estimated volatility 148.3% - 148.8 % Expected dividend — Stock price at valuation date $0.31 – $0.45

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Oct. 31, 2020
Warrants Abstract
Schedule of additional warrants	The following is a table of warrants issued in connection with the PIPE deal during the three months ended October 31, 2020: Initial Exercise Price Initial Warrants Issued Additional Warrants Issued Reset Exercise Price Outstanding Warrants as of October 31, 2020 Series A Warrants $ 0.392 5,102,040 5,112,463 $ 0.196 10,214,503 Series B Warrants $ 0.392 15,306,120 15,337,389 $ 0.196 30,643,509 Series C Warrants $ 0.539 10,204,080 9,142,973 $ 0.281 19,347,053 Total Warrants from PIPE deal 30,612,240 29,592,825 60,205,065
Schedule of warrant activities	A summary of the Company’s warrant activities is as follows: Number of Warrants Weighted Average Exercise Price per Share Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Outstanding - July 31, 2020 567,553 $ 2,50 2.20 $ — Issued 69,348,038 0.19 5 7,546,985 Exercised (9,142,973 ) 0.001 5 1,892,595 Expired — — — — Outstanding – October 31, 2020 60,772,618 $ 0.24 4.99 $ 5,654,389

Net Income Per Share (EPS) (Tab

Net Income Per Share (EPS) (Tables)	3 Months Ended
	Oct. 31, 2020
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common shareholders because including them would have been anti-dilutive for the years ended October 31, 2020 and 2019, respectively. Three Months Ended October 31, 2020 2019 Convertible debt 16,867,885 5,061,647 Stock options 12,922,360 9,339,195 Warrants 60,772,618 21,567,553 Total 90,562,863 35,968,395

Organization of Business and _2

Organization of Business and Going Concern (Details Narrative) - USD ($)	Jan. 07, 2019	Aug. 25, 2020	Oct. 31, 2020	Oct. 31, 2019	Jul. 31, 2020
Accumulated deficit			$ (464,643,597)		$ (452,062,905)
Working capital deficiency			(50,399,602)
Secured promissory note Description	On January 7, 2019, the Company closed two separate Acquisition Agreements pursuant to which the Company acquired a 51% interest in both Regentys Corporation (“Regentys”) and OlaregenTherapeutix Inc. (“Olaregen”). Regentys is a regenerative medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders. Olaregen is a New York based regenerative medicine company that is preparing to launch its proprietary, patented, wound conforming gel matrix, Excellagen, an FDA 510K cleared wound healing product. In the first quarter of 2020 the Company acquired increased its ownership of Olaregen to 77%.
Revenue			$ 88,435	$ 721,661
Medisource and Pantheon
Revenue				$ 449,196
WWDT
Proceeds from related party		$ 1,500,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Revenue recognised	$ 88,435	$ 721,661
Product [Member]
Revenue recognised	88,435	713,405
Management Services [Member]
Revenue recognised	$ 0	$ 8,256

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)

Oct. 05, 2020

Dec. 02, 2019

Dec. 03, 2018

Sep. 18, 2020

Jul. 31, 2020

Feb. 18, 2020

Nov. 27, 2019

Nov. 25, 2019

Nov. 24, 2019

Nov. 22, 2019

Aug. 22, 2017

Dec. 31, 2011

Oct. 31, 2020

Oct. 31, 2019

Nov. 16, 2012

May 04, 2020

Apr. 24, 2020

May 31, 2019

Dec. 02, 2018

Oct. 26, 2018

Settlement of litigation

$ 200,000

Commitments and Contingencies

The letter from AEXG counsel claimed that Generex’s acceptance of $3,000,000 in financing from Pharma Trials, LLC, in March 2017, violated the provisions of the MOU prohibiting Generex from seeking other financing, with certain exceptions, for a period of 60 days after execution of the MOU. AEXG has demanded at least $210,000 in cash and 84,000 warrants for Generex stock convertible at $2.50 per share, for attorney’s fees and costs.

Litigation awards for damages

$ 315,695

384,771

Litigation awards, exercisable shares

84,000

84,000

Exercise price

$ 2.50

$ 2.50

Note amount

$ 446,600

$ 2,882,000

$ 2,000,000

$ 682,000

Original issue discount

425,302

251,253

Accrued Liquidated damages

210,000

Accrued claim

2,752,235

Legal fees

93,304

Research and development

1,170,008

$ 338,734

Payable to foundation for services

1,315,817

1,315,817

Interest payable to foundation

$ 3,911,141

4,149,900

Interest accrued payable to foundation

238,759

199,685

Arbitration fees

12,393

Arbitration expenses

3,313

Proceeds from refundable advances

2,000,000

Bonus

$ 7,005,416

Pre-judgment interest

$ 65,762

Bonus compensation description

Company awarded executives and employees bonus compensation of $7,005,416 to be paid in approximately $1 million in cash and $6 million in stock.

Accrued claim

$ 450,000

COVID-19 Collaboration Agreement [Member] | Pre-Commercialization Stage [Member]

Legal fees

$ 2,625,000

COVID-19 Collaboration Agreement [Member] | Commercialization Stage [Member]

Legal fees

$ 10,000,000

Olaregen

Intellectual property acquired

$ 650,000

KSKZ Management [Member]

Consulting fees

$ 3,450,000

Damages

$ 2,475,000

Discover Growth Fund [Member]

Accrued claim

$ 2,200,000

Iliad [Member]

Shares issued for litigation settlement

3,499,415

ALTuCELL [Member]

Common stock description

Under the SPA, in exchange for the ALTuCELL Stock, Generex will issue to ALTuCELL 2,240,000 shares of Generex common stock with an attributed value of $4 million to be issued at the market price of the day at closing, but no less than $0.89 per share. The Company will also pay $2.5 million in cash of which $212,000 has already been paid. In addition to stock and cash at closing, Generex has agreed to pay up to an aggregate of $3,500,000 to ALTuCELL upon ALTuCELL’s attainment of certain milestones.

Advanced to related party

212,000

NDS

Accrued claim

3,416,695

Alternative Execution Group [Member]

Memorandum of Understanding description

The petition includes a demand of $3,300,360 as the value of the warrants. The arbitrator did not award the specific amount of $3.5 million, but only liquidated damages in the amount of $210,000 and the value of 84,000 warrants “as of today” (the date of the award) plus attorney’s fees, certain costs, prejudgment and post-judgment interest (which continues to run on a daily basis) and arbitration fees.

Olaregen

Stock Purchase Agreement description

Company amended the Stock Purchase Agreement with Olaregen. The Company was obligated to pay in full $11,600,000 to Olaregen by November 30, 2019, in connection with the purchase of Olaregen capital stock (the “Olaregen Note”). Effective November 24, 2019, the deadline was extended to January 31, 2020.

Regentys

Stock Purchase Agreement description

Company amended the Stock Purchase Agreement with Regentys originally on January 7, 2019. Effective November 25, 2019, the remaining three payments of $2,039,001, $2,000,000, and $3,000,000 were all payable on or before December 30, 2019. The Company is negotiating the terms of a new extension and there has been no demand for payment at this time.

NSABP [Member] | Clinical trial agreement [Member]

Accrued claim

562,063

Research and development

0

$ 251,765

Damages for Unpaid Invoices

Value of damages sought

$ 429,000

Lawsuit filing date

31-Dec-11

Name of Plaintiff

Vendor

Settlement of litigation

$ 125,000

Interest per annum, failure to pay settlement

3.00%

Fixed cost per annum, failure to pay settlement

$ 25,000

Breach of contract and detinue

Counterclaim proceeding

$ 200,000

Inventory (Details)

Inventory (Details) - USD ($)	Oct. 31, 2020	Jul. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 182,722	$ 182,722
Finished goods	535,902	559,534
Total Inventory	$ 718,624	$ 742,256

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Oct. 31, 2020	Jul. 31, 2020
Property and equipment	$ 386,681	$ 418,612
Less accumulated depreciation	(211,168)	(204,944)
Property and equipment, net	175,513	213,668
Computers and technological assets
Property and equipment	50,205	53,314
Machinery and Equipment [Member]
Property and equipment	317,751	329,977
Furniture and Fixtures [Member]
Property and equipment	18,725	18,725
Leasehold Improvements [Member]
Property and equipment	$ 0	$ 16,596

Property and Equipment (Detai_2

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 30,831	$ 48,847
Loss on disposal of fixed assets	$ (7,324)	$ 0

Goodwill and Intangible Assets_

Goodwill and Intangible Assets: Intangible assets (Details) - USD ($)	3 Months Ended
	Oct. 31, 2020	Jul. 31, 2020
Intangible assets gross	$ 10,153,701	$ 10,153,701
Less accumulated amortization	(1,019,517)	(788,175)
Intangible assets net	9,134,184	9,365,526
Noncompete Agreements [Member]
Intangible assets gross	$ 1,210,000	1,210,000
Estimated Useful Lives	3 years
Developed Software/Technology [Member]
Intangible assets gross	$ 131,000	131,000
Estimated Useful Lives	5 years
Intellectual Property [Member]
Intangible assets gross	$ 2,459,000	2,459,000
Estimated Useful Lives	5 years
Patents [Member]
Intangible assets gross	$ 51,274	51,274
Estimated Useful Lives	20 years
In Process Research and Development [Member]
Intangible assets gross	$ 6,302,427	$ 6,302,427

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets: Estimated amortization expense (Details)	Oct. 31, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
For the nine months ended July 31, 2021	$ 692,555
2022	654,190
2023	520,564
2024	500,914
2025	458,202
Thereafter	5,332
Total	$ 2,831,757

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets (Details Narrative) - USD ($)	3 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Jul. 31, 2020
Amortization expense	$ 231,342	$ 154,426
Intangible assets gross	10,153,701		$ 10,153,701
Goodwill	34,489,342		34,489,342
In Process Research and Development [Member]
Intangible assets gross	6,302,427		$ 6,302,427
In Process Research and Development [Member] | HDS [Member]
Intangible assets gross	2,911,377
In Process Research and Development [Member] | Regentys
Intangible assets gross	3,391,050
In Process Research and Development [Member] | Olaregen
Intangible assets gross	$ 2,459,000

Notes Payable (Details)

Notes Payable (Details) - USD ($)	3 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Debt Disclosure [Abstract]
Balance of notes paybale at beginning	$ 11,166,359
Increase in debt due to default	255,080
Amortization of debt discount	174,049	$ 2,065,835
Conversions	(1,077,086)
Payments	(60,000)
Balance of notes payable at end	$ 10,458,402

Notes Payable (Details 1)

Notes Payable (Details 1) - USD ($)	Oct. 31, 2020	Jul. 31, 2020
Debt Disclosure [Abstract]
Notes payable	$ 10,709,655	$ 11,591,661
Less: debt discount	(251,253)	(425,302)
Total debt, net of discount	10,458,402	11,166,359
Notes payable, net - noncurrent	499,839	499,656
Notes payable, net - current	$ 9,958,563	$ 10,666,703

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Aug. 11, 2020	May 04, 2020	Feb. 10, 2020	Jun. 25, 2020	Apr. 30, 2020	Feb. 28, 2020	Feb. 19, 2020	Dec. 31, 2019	Aug. 31, 2019	May 31, 2019	Oct. 26, 2018	Dec. 28, 2017	Oct. 31, 2020	Jan. 31, 2020	Oct. 31, 2019	Aug. 31, 2020	Jul. 31, 2020	Apr. 24, 2020	Apr. 09, 2020	Dec. 02, 2018
Note amount										$ 2,000,000	$ 682,000		$ 2,882,000				$ 446,600
Purchase price of note									$ 1,000,000		550,000	$ 320,000
Investor fee											15,000
Original issue discount									$ 150,000		$ 147,000
Effective interest											24.00%	3.00%
Interest rate							22.00%		10.00%	7.00%
Due date										Aug. 1, 2019	Oct. 26, 2019
Payment of Promissory Note												$ 3,413,000
Common stock issued for conversion debt, Shares	3,499,415												5,860,255		1,164,190
Common stock issued for conversion debt, Value	$ 1,459,676						$ 956,535						$ 1,127,842		$ 1,736,837
Debt discount													251,253				425,302
Notes payable													10,458,402				$ 11,166,359
Exercise price																		$ 2.50		$ 2.50
Subsidiaries [Member]
Interest rate					100.00%
Proceeds from loan					$ 499,473
Regentys
Note amount													349,656
Accrued interest													95,885
Debt discount													$ 16,824
Minimum [Member]
Interest rate													22.00%
Maximum [Member]
Interest rate													24.00%
Principal
Common stock issued for conversion debt, Value	772,500						772,500						$ 615,000
Interest
Common stock issued for conversion debt, Value	$ 687,176						$ 184,035
TwoNotes [Member]
Note amount													2,882,000
lender [Member]
Note amount																			$ 50,000
Effective interest																			10.00%
lender [Member] | Promissory note [Member]
Note amount		$ 100,000
Effective interest		10.00%
Payment of Promissory Note		$ 60,000
Common stock issued for conversion debt, Shares		20,000
Notes payable													$ 90,000
Options issued		20,000
Exercise price		$ 0.43
Securities Purchase Agreements [Member] | Investors
Note amount			$ 305,000	$ 150,000				$ 2,200,000
Purchase price of note			270,000	145,000				2,000,000
Original issue discount			30,000	$ 5,000				$ 200,000
Interest rate				12.00%				12.00%	10.00%					10.00%
Derivative liability			$ 131,703	$ 59,985				$ 111,508
Securities Purchase Agreements [Member] | Investor
Note amount						$ 281,600										$ 1,100,000
Purchase price of note						256,000										1,000,000
Original issue discount						$ 31,600										100,000
Interest rate			12.00%			9.50%
Common stock issued for conversion debt, Shares			35,000
Derivative liability						$ 128,219										$ 521,383
Closing costs			$ 5,000

Derivative Liability (Details)

Derivative Liability (Details)	3 Months Ended
	Oct. 31, 2020USD ($)
Derivative liabilities at beginning	$ 1,316,757
Additions during the period	21,574,216
Change in fair value	(4,019,852)
Change due to conversion / exercise	(2,378,614)
Derivative liabilities at end	16,492,507
Derivative Liability Convertible Notes
Derivative liabilities at beginning	742,391
Additions during the period	0
Change in fair value	111,150
Change due to conversion / exercise	(538,084)
Derivative liabilities at end	315,457
Derivative Liability Warrants
Derivative liabilities at beginning	574,366
Additions during the period	21,574,216
Change in fair value	(4,131,002)
Change due to conversion / exercise	(1,840,530)
Derivative liabilities at end	$ 16,177,050

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	3 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Equity [Abstract]
Balance as of July 31, 2020	$ 10,079,449
Issuance of common stock payable	(1,472,826)
Change in fair value of common stock payable	(123,230)	$ 0
Balance as of October 31, 2020	$ 8,483,393

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Aug. 11, 2020	Aug. 04, 2020	Jul. 14, 2020	Sep. 12, 2019	Jan. 07, 2019	Oct. 31, 2020	Feb. 19, 2020	Nov. 25, 2019	Aug. 31, 2019	Oct. 31, 2020	Oct. 31, 2019	Oct. 12, 2020	Sep. 28, 2020	Jul. 31, 2020	Feb. 14, 2020
Stock compensation expense										$ 1,210,859
Issuance of common stock payable, shares										3,529,415	296,793
Issuance of common stock payable, amount										$ 1,472,826	$ 921,895
Common stock to be issued										8,483,393	10,079,449
Common stock issued for conversion debt, Shares	3,499,415									5,860,255	1,164,190
Common stock issued for conversion debt, Value	$ 1,459,676						$ 956,535			$ 1,127,842	$ 1,736,837
Decrease in derivative liability										$ 538,084	1,911,487
Cancellation of common stock				20,375,900
Common stock, shares outstanding						108,037,614				108,037,614				82,251,801
Common stock, shares issued						108,037,614				108,037,614				82,251,801
Proceeds from issuance of stock										$ 356,710	$ 0
Warrants issued		30,612,240											29,592,825
Exercise price						$ 0.24				$ 0.24				$ 250
Deemed dividend										$ 1,850,000
Decrease in Accumulated Deficit										$ 1,850,000
Series A Warrants [Member]
Exercise price						0.392				$ 0.392
Series B Warrants [Member]
Exercise price						0.392				0.392
Series C Warrants [Member]
Exercise price						$ 0.539				$ 0.539
Series D Warrants [Member]
Exercise price												$ 0.001	$ 0.001
Medisource
Common stock issued for acquisition									400,000
Stock Price									$ 2.50
Pantheon [Member]
Common stock issued for acquisition									560,000
Stock Price									$ 2.50
Olaregen
LOI Terms					Pursuant to the Company’s acquisition of Olaregen on January 7, 2019 to acquire a 51% interest, the Company was issued 3,282,632 shares of Olaregen common stock from Olaregen shareholders. In May 2019, the Company issued 4,000,000 shares of common stock contributed and provided by the Friends of Generex Trust and a $2 million note payable for the acquisition of 592,683 shares of Series A Preferred Stock of Olaregen pursuant to a Stock Purchase Agreement entered into January 14, 2019 subject to the approval of the Board of Directors of Olaregen and consummated on May 10, 2019. The provided shares by the Friends of Generex Trust were already issued and outstanding and did not result in any expense of the Company. Since these shares were transferred, to the shareholders of Olaregen, by an existing shareholder to settle an obligation of the Company, the value of the shares provided by the Friends of the Generex Trust to settle the debt was reflected in the financial statements as an addition to contributed (paid-in) capital.
Common stock, shares outstanding															5,950,000
NGIO
Common stock, shares outstanding						400,300,000				400,300,000					2,765,000
Common stock, shares issued						400,300,000				400,300,000
Non-controlling interest						36,296,849				36,296,849
Percentage of non-controlling interest						9.07%				9.07%
Regentys
LOI Terms					Pursuant to the Company’s acquisition of Regentys on January 7, 2019 to acquire a 51% interest, the Company was issued 12,048,161 shares of Regentys common stock. As of January 31, 2020, Regentys had a total of 18,623,278 shares of common stock and 2,793,192 Series A voting preferred stock for a total of 21,416,470 total voting shares outstanding. As such, there are 9,368,309 of shares that belong to non-controlling interest shareholders which represents a 43.74% non-controlling interest
Share Exchange Agreement | Olaregen
Number of shares exchanged			300,000
Vendors
Stock Issued During Period, Shares Issued for Services						51,130
Stock Issued During Period, Value, Issued for Services						$ 10,993
Oasis Capital, LLC | Equity Purchase Agreement [Member]
Common stock purchased								$ 40,000,000
Number of common stock issued								2,100,000
Purchase price of shares								$ 356,710
Accredited Investors [Member] | Security Purchase Agreement [Member]
Number of common stock issued		5,102,040
Proceeds from issuance of stock		$ 1,850,000
Attorneys fees		$ 150,000
Shares issued price per share		$ 0.001
Accredited Investors [Member] | Security Purchase Agreement [Member] | Series A Warrants [Member]
Shares reserved for future issuance													10,214,503
Warrants issued		5,102,040											5,112,463
Exercise price		$ 0.392											$ 0.1958
Accredited Investors [Member] | Security Purchase Agreement [Member] | Series B Warrants [Member]
Shares reserved for future issuance													30,643,509
Warrants issued		15,306,122											15,337,389
Accredited Investors [Member] | Security Purchase Agreement [Member] | Series C Warrants [Member]
Shares reserved for future issuance													19,347,053
Warrants issued													9,142,973
Exercise price		$ 0.539											$ 0.28149
Accredited Investors [Member] | Security Purchase Agreement [Member] | Series D Warrants [Member]
Shares reserved for future issuance													9,142,973
Warrants issued													9,142,973
Exercise price		$ 0.001											$ 0.001

Redeemable Non-Controlling In_2

Redeemable Non-Controlling Interest (Details Narrative) - USD ($)	Oct. 31, 2020	Jul. 31, 2020
Notes to Financial Statements
Redeemable Non-Controlling Int	$ 4,073,898	$ 4,073,898

Stock-Based Compensation - Comm

Stock-Based Compensation - Common stock options granted, forfeited or expired and exercised (Details) - USD ($)	3 Months Ended	12 Months Ended
	Oct. 31, 2020	Jul. 31, 2019
Share-based Payment Arrangement [Abstract]
Options Outstanding, Beginning	8,847,025
Options Granted	6,222,210
Options Forfeited or expired	(2,146,875)
Options Exercised	0
Options Outstanding, End	12,922,360
Weighted Average Exercise Price per Share, Beginning	$ 0.9
Weighted Average Exercise Price per Share, Granted	0.35
Weighted Average Exercise Price per Share, Forfeited or expired	0.82
Weighted Average Exercise Price per Share, Exercised	0
Weighted Average Exercise Price per Share, End	$ 0.65
Weighted Average Remaining Life Options Outstanding (Years)	7 years 6 months 7 days	5 years 11 months 15 days
Weighted Average Remaining Life Options Granted	9 years 10 months 3 days
Weighted Average Remaining Life Options Forfeited or expired	6 years 9 months
Aggregate Intrinsic Value Options, Outstanding Beginning	$ 508,932
Aggregate Intrinsic Value Options Granted	0
Aggregate Intrinsic Value Options, Outstanding Ending	$ 130,315

Stock-Based Compensation - Non-

Stock-Based Compensation - Non-vested Options granted, forfeited or expired and exercised (Details)	3 Months Ended
	Oct. 31, 2020$ / sharesshares
Non-vested Options Expired	0
Non-vested Options [Member]
Non-vested Options Outstanding, Beginning	4,082,767
Non-vested Options Granted	6,222,210
Non-vested Options Expired	0
Non-vested Options Cancelled	(366,667)
Non-vested Options Vested	(2,459,053)
Non-vested Options Outstanding, End	7,479,257
Weighted Average Grant Date Fair value, Beginning | $ / shares	$ 1.06
Weighted Average Grant Date Fair value, Granted | $ / shares	0.35
Weighted Average Grant Date Fair value, Expired | $ / shares	0
Weighted Average Grant Date Fair value, Cancelled | $ / shares	0.79
Weighted Average Grant Date Fair value, Vested | $ / shares	0.59
Weighted Average Grant Date Fair value, End | $ / shares	$ 0.64

Stock-Based Compensation - Fair

Stock-Based Compensation - Fair value assumptions used in Black-Scholes option-pricing (Details)	3 Months Ended
	Oct. 31, 2020$ / shares
Time to expiration	10 years
Expected dividend	0.00%
Minimum [Member]
Exercise price	$ 0.31
Risk-free interest rate	0.16%
Estimated volatility	148.30%
Stock price at valuation date	$ 0.31
Maximum [Member]
Exercise price	$ 0.45
Risk-free interest rate	0.18%
Estimated volatility	148.80%
Stock price at valuation date	$ 0.45

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	2 Months Ended	3 Months Ended
	Sep. 30, 2020	Oct. 31, 2020	Oct. 31, 2019
Market value		$ 0.208
Compensation expense		$ 1,221,852	$ 787,458
Stock Option Plan 2006
Common stock reserved for future issuance		0
Common stock reserved for future awards		0
Options vested		5,443,103
Stock Option Plan 2017
Common stock reserved for future issuance		240,000,000
Common stock reserved for future awards		229,077,640
Stock Option Plan 2019
Common stock reserved for future issuance		1,680,000
Stock Options
Compensation expense		$ 1,211,007
Unrecognized compensation costs		$ 3,936,129
Unrecognized compensation period		2 years 1 month 2 days
Stock Options | Officers
Options granted	6,222,210
Options granted per share	$ 0.45
Stock Options | Minimum [Member]
Vesting period		0 months
Stock Options | Maximum [Member]
Vesting period		48 months

Warrants (Details)

Warrants (Details) - $ / shares	Oct. 31, 2020	Jul. 31, 2020	Apr. 24, 2020	Dec. 02, 2018
Initial Exercise Price	$ 0.24	$ 250
Reset Exercise Price			$ 2.50	$ 2.50
Total Warrants from PIPE deal	60,772,618	567,553
Series A Warrants [Member]
Initial Exercise Price	$ 0.392
Initial Warrants Issued	5,102,040
Additional Warrants Issued	5,112,463
Reset Exercise Price	$ 0.196
Total Warrants from PIPE deal	10,214,503
Series B Warrants [Member]
Initial Exercise Price	$ 0.392
Initial Warrants Issued	15,306,120
Additional Warrants Issued	15,337,389
Reset Exercise Price	$ 0.196
Total Warrants from PIPE deal	30,643,509
Series C Warrants [Member]
Initial Exercise Price	$ 0.539
Initial Warrants Issued	10,204,080
Additional Warrants Issued	9,142,973
Reset Exercise Price	$ 0.281
Total Warrants from PIPE deal	19,347,053
Warrants [Member]
Initial Warrants Issued	30,612,240
Additional Warrants Issued	29,592,825
Total Warrants from PIPE deal	60,205,065

Warrants (Details 1)

Warrants (Details 1)	3 Months Ended
	Oct. 31, 2020USD ($)$ / sharesshares
Warrants Abstract
Number of Warrants Outstanding at beginning	567,553
Number of Warrants Issued	69,348,038
Number of Warrants Exercised	(9,142,973)
Number of Warrants Expired	0
Number of Warrants Outstanding at end	60,772,618
Weighted Average Exercise Price per Share Outstanding at beginning | $ / shares	$ 250
Weighted Average Exercise Price per Share Issued	0.19
Weighted Average Exercise Price per Share Exercied | $ / shares	$ 0.001
Weighted Average Exercise Price per Share Expired | $ / shares	0
Weighted Average Exercise Price per Share Outstanding at end | $ / shares	$ 0.24
Weighted Average Remaining Life of Warrants Outstanding at beginning (Years)	2 years 2 months 12 days
Weighted Average Remaining Life of Warrants Issued	5 years
Weighted Average Remaining Life of Warrants Exercised	5 years
Weighted Average Remaining Life of Warrants Outstanding at end (Years)	4 years 11 months 26 days
Aggregate Intrinsic Value Warrants Outstanding at beginning | $	$ 0
Aggregate Intrinsic Value Warrants issued | $	7,546,985
Aggregate Intrinsic Value Warrants Exercised | $	1,892,595
Aggregate Intrinsic Value Warrants Outstanding at end | $	$ 5,654,389

Warrants (Details Narrative)

Warrants (Details Narrative) - $ / shares	Oct. 31, 2020	Oct. 12, 2020	Sep. 28, 2020	Aug. 04, 2020	Jul. 31, 2020
Warrants outstanding	60,772,618				567,553
Warrants issued			29,592,825	30,612,240
Exercise price	$ 0.24				$ 250
Series D Warrants [Member]
Number of Warrants issued and exercised	9,142,973	3,480,783	5,662,190
Exercise price		$ 0.001	$ 0.001

Net Income Per Share (EPS) - Sc

Net Income Per Share (EPS) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Total	90,562,863	35,968,395
Convertible Debt
Total	16,867,885	5,061,647
Stock options
Total	12,922,360	9,339,195
Warrants
Total	60,772,618	21,567,553

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Oct. 31, 2020	Jul. 31, 2019
Pre-tax gain or (loss) arising from domestic operations	$ (10,982,942)	$ (34,291,142)
Pre-tax (losses) arising from foreign operations	(6,134)	$ 59,049
NOL carryforwards	219,700,000
Decrease in deferred tax assets	73,000,000
Generex Pharmaceuticals
NOL carryforwards	34,400,000
NGIO
NOL carryforwards	35,700,000
Regentys
NOL carryforwards	6,600,000
Olaregen
NOL carryforwards	4,100,000
Veneto
NOL carryforwards	$ 10,600,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Dec. 07, 2020	Nov. 13, 2020	Nov. 09, 2020	Nov. 25, 2020	Nov. 19, 2020	Nov. 18, 2020	Nov. 17, 2020	Oct. 31, 2020
Options exercised								0
Subsequent Event [Member]
Agreement description		The Agreement, among other things, consists of the Joint Entity providing 100% funding for the clinical development, manufacturing and commercial registration of the Vaccine for China and paying Generex licensing and royalty fees as follows: 1. Licensing Fee: $5,000,000 upfront fee due upon the execution of the Agreement; and then upon a successfully approved Vaccine, and an additional $20,000,000 from the net profits from the Joint Entity. 2. Royalty Fee: Once the Vaccine comes on to market for the first commercial sale, then the Joint Entity shall:
Contracted amount					$ 273,000		$ 82,780
Project cost				$ 130,135
Subsequent Event [Member] | Minimum [Member]
Project cost	$ 1,127,000
Subsequent Event [Member] | Maximum [Member]
Project cost	$ 1,530,000
Subsequent Event [Member] | Oasis [Member]
Options exercised			1,750,000			1,750,000
Proceeds from options exercised			$ 306,939			$ 306,939